{"data": [{"text": "RT @chadinabhan: Great to spend time with @VincentRK @AaronGoodman33 @JatinShahMD and Dr. Park (not of twitter; we are trying) speaking wit\u2026", "conversation_id": "1601410660222783489", "lang": "en", "author_id": "854692626015993857", "id": "1601410660222783489", "referenced_tweets": [{"type": "retweeted", "id": "1601409465948872704"}], "entities": {"mentions": [{"start": 3, "end": 15, "username": "chadinabhan", "id": "2212735524"}, {"start": 42, "end": 52, "username": "VincentRK", "id": "24261916"}, {"start": 53, "end": 68, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 69, "end": 81, "username": "JatinShahMD", "id": "221642631"}]}, "edit_history_tweet_ids": ["1601410660222783489"], "source": "Twitter for iPhone", "created_at": "2022-12-10T02:57:08.000Z"}, {"text": "Awesome to meet in real life.  Amazing guy and mentor (I\u2019m not talking about Chadi) https://t.co/m2GdrDh8r4", "conversation_id": "1601401098735996928", "lang": "en", "author_id": "854692626015993857", "id": "1601401098735996928", "referenced_tweets": [{"type": "quoted", "id": "1601400573555019776"}], "entities": {"annotations": [{"start": 77, "end": 81, "probability": 0.6136, "type": "Other", "normalized_text": "Chadi"}], "urls": [{"start": 84, "end": 107, "url": "https://t.co/m2GdrDh8r4", "expanded_url": "https://twitter.com/chadinabhan/status/1601400573555019776", "display_url": "twitter.com/chadinabhan/st\u2026"}]}, "edit_history_tweet_ids": ["1601401098735996928"], "source": "Twitter for iPhone", "created_at": "2022-12-10T02:19:09.000Z"}, {"text": "@DSparky1 @acweyand Ran 13 miles. Walked 7 miles.  I will eat tonight", "conversation_id": "1601285083566161922", "lang": "en", "author_id": "854692626015993857", "id": "1601354744424910848", "referenced_tweets": [{"type": "replied_to", "id": "1601317972932726784"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "DSparky1", "id": "20281991"}, {"start": 10, "end": 19, "username": "acweyand", "id": "824315782947631104"}]}, "edit_history_tweet_ids": ["1601354744424910848"], "in_reply_to_user_id": "20281991", "source": "Twitter for iPhone", "created_at": "2022-12-09T23:14:57.000Z"}, {"text": "@acweyand Your curl game is strong https://t.co/QcI9ABK9GD", "conversation_id": "1601350353915875330", "lang": "en", "author_id": "854692626015993857", "id": "1601352964995969025", "referenced_tweets": [{"type": "replied_to", "id": "1601350353915875330"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "acweyand", "id": "824315782947631104"}], "urls": [{"start": 35, "end": 58, "url": "https://t.co/QcI9ABK9GD", "expanded_url": "https://twitter.com/AaronGoodman33/status/1601352964995969025/photo/1", "display_url": "pic.twitter.com/QcI9ABK9GD", "media_key": "3_1601352956246462466"}]}, "edit_history_tweet_ids": ["1601352964995969025"], "in_reply_to_user_id": "824315782947631104", "source": "Twitter for iPhone", "created_at": "2022-12-09T23:07:53.000Z"}, {"text": "Anticoagulation in women.  \n\nExcellent read and very useful info for clinic!\n#ASH22. https://t.co/z6lsHFuCHi", "conversation_id": "1601350291424964613", "lang": "en", "author_id": "854692626015993857", "id": "1601350291424964613", "referenced_tweets": [{"type": "quoted", "id": "1601328957978456064"}], "edit_history_tweet_ids": ["1601350291424964613"], "entities": {"urls": [{"start": 85, "end": 108, "url": "https://t.co/z6lsHFuCHi", "expanded_url": "https://twitter.com/bloodman/status/1601328957978456064", "display_url": "twitter.com/bloodman/statu\u2026"}], "hashtags": [{"start": 77, "end": 83, "tag": "ASH22"}]}, "source": "Twitter for iPhone", "created_at": "2022-12-09T22:57:15.000Z"}, {"text": "As usual I will read the #ASH22 Education Book cover to cover and will try and do a 1 tweet summary for each chapter of key points.  This is how I keep up. https://t.co/eyNVMnp9cN", "conversation_id": "1601347400006012930", "lang": "en", "author_id": "854692626015993857", "id": "1601347400006012930", "referenced_tweets": [{"type": "quoted", "id": "1601300744644472832"}], "edit_history_tweet_ids": ["1601347400006012930"], "entities": {"urls": [{"start": 156, "end": 179, "url": "https://t.co/eyNVMnp9cN", "expanded_url": "https://twitter.com/aarongoodman33/status/1601300744644472832", "display_url": "twitter.com/aarongoodman33\u2026"}], "hashtags": [{"start": 25, "end": 31, "tag": "ASH22"}]}, "source": "Twitter for iPhone", "created_at": "2022-12-09T22:45:46.000Z"}, {"text": "@strouse_chris @nihardesai7 Agree with you.  In practice score not useful", "conversation_id": "1601335757213696003", "lang": "en", "author_id": "854692626015993857", "id": "1601346731551383552", "referenced_tweets": [{"type": "replied_to", "id": "1601342476056670208"}], "entities": {"mentions": [{"start": 0, "end": 14, "username": "strouse_chris", "id": "898851661"}, {"start": 15, "end": 27, "username": "nihardesai7", "id": "75550503"}]}, "edit_history_tweet_ids": ["1601346731551383552"], "in_reply_to_user_id": "898851661", "source": "Twitter for iPhone", "created_at": "2022-12-09T22:43:07.000Z"}, {"text": "@nihardesai7 No age. But when I start seeing some frailty it\u2019s just not worth it to transplant  anymore", "conversation_id": "1601335757213696003", "lang": "en", "author_id": "854692626015993857", "id": "1601337861814759424", "referenced_tweets": [{"type": "replied_to", "id": "1601336046696165377"}], "entities": {"mentions": [{"start": 0, "end": 12, "username": "nihardesai7", "id": "75550503"}]}, "edit_history_tweet_ids": ["1601337861814759424"], "in_reply_to_user_id": "75550503", "source": "Twitter for iPhone", "created_at": "2022-12-09T22:07:52.000Z"}, {"text": "Practice changer!\n\nMEL140 fails to beat Rd in older patients with myeloma.  I don\u2019t plan on doing much auto anymore in patients with myeloma who are older.\n\n#ASH22 https://t.co/WDGc8SuDRO", "conversation_id": "1601335757213696003", "lang": "en", "author_id": "854692626015993857", "id": "1601335757213696003", "referenced_tweets": [{"type": "quoted", "id": "1601305074629648385"}], "entities": {"annotations": [{"start": 19, "end": 24, "probability": 0.5335, "type": "Other", "normalized_text": "MEL140"}, {"start": 40, "end": 41, "probability": 0.7885, "type": "Other", "normalized_text": "Rd"}, {"start": 66, "end": 72, "probability": 0.7812, "type": "Other", "normalized_text": "myeloma"}, {"start": 133, "end": 139, "probability": 0.7358, "type": "Other", "normalized_text": "myeloma"}, {"start": 158, "end": 162, "probability": 0.4897, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 164, "end": 187, "url": "https://t.co/WDGc8SuDRO", "expanded_url": "https://twitter.com/mannimd1/status/1601305074629648385", "display_url": "twitter.com/mannimd1/statu\u2026"}], "hashtags": [{"start": 157, "end": 163, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1601335757213696003"], "source": "Twitter for iPhone", "created_at": "2022-12-09T21:59:30.000Z"}, {"text": "@ManniMD1 Good abstract", "conversation_id": "1601305074629648385", "lang": "en", "author_id": "854692626015993857", "id": "1601334515880046592", "referenced_tweets": [{"type": "replied_to", "id": "1601305074629648385"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}]}, "edit_history_tweet_ids": ["1601334515880046592"], "in_reply_to_user_id": "1269642863924609025", "source": "Twitter for iPhone", "created_at": "2022-12-09T21:54:34.000Z"}, {"text": "Awesome work by @UCSDAnes and the legendary Dr. Aleck!\n\n@AleckAmalia https://t.co/KAOiObyiCy", "conversation_id": "1601314763203829761", "lang": "en", "author_id": "854692626015993857", "id": "1601314763203829761", "referenced_tweets": [{"type": "quoted", "id": "1601063795941482497"}], "entities": {"mentions": [{"start": 16, "end": 25, "username": "UCSDAnes", "id": "1542877210356330497"}, {"start": 56, "end": 68, "username": "AleckAmalia", "id": "1331336294828437504"}], "urls": [{"start": 69, "end": 92, "url": "https://t.co/KAOiObyiCy", "expanded_url": "https://twitter.com/ucsdanes/status/1601063795941482497", "display_url": "twitter.com/ucsdanes/statu\u2026"}]}, "edit_history_tweet_ids": ["1601314763203829761"], "source": "Twitter for iPhone", "created_at": "2022-12-09T20:36:05.000Z"}, {"text": "RT @mattwilson2287: Check out our (+ @sabobillo @CwynKate) review on #CNSprophylaxis in this year's educational book\nhttps://t.co/3eq1rMVIZ\u2026", "conversation_id": "1601307961770397696", "lang": "en", "author_id": "854692626015993857", "id": "1601307961770397696", "referenced_tweets": [{"type": "retweeted", "id": "1601307741355913217"}], "entities": {"mentions": [{"start": 3, "end": 18, "username": "mattwilson2287", "id": "45443577"}, {"start": 37, "end": 47, "username": "sabobillo", "id": "829364688018407425"}, {"start": 48, "end": 57, "username": "CwynKate", "id": "879789995053240321"}], "annotations": [{"start": 70, "end": 83, "probability": 0.78, "type": "Other", "normalized_text": "CNSprophylaxis"}], "hashtags": [{"start": 69, "end": 84, "tag": "CNSprophylaxis"}]}, "edit_history_tweet_ids": ["1601307961770397696"], "source": "Twitter for iPhone", "created_at": "2022-12-09T20:09:03.000Z"}, {"text": "@acweyand Yes.  They are open 24 hours a day.  I plan for a late night session again tonight", "conversation_id": "1601285083566161922", "lang": "en", "author_id": "854692626015993857", "id": "1601301938712125440", "referenced_tweets": [{"type": "replied_to", "id": "1601301763319300096"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "acweyand", "id": "824315782947631104"}]}, "edit_history_tweet_ids": ["1601301938712125440"], "in_reply_to_user_id": "824315782947631104", "source": "Twitter for iPhone", "created_at": "2022-12-09T19:45:07.000Z"}, {"text": "@acweyand Amazing", "conversation_id": "1601285083566161922", "lang": "en", "author_id": "854692626015993857", "id": "1601301419155288065", "referenced_tweets": [{"type": "replied_to", "id": "1601301238536028160"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "acweyand", "id": "824315782947631104"}]}, "edit_history_tweet_ids": ["1601301419155288065"], "in_reply_to_user_id": "824315782947631104", "source": "Twitter for iPhone", "created_at": "2022-12-09T19:43:03.000Z"}, {"text": "Yes the ASH Education Book has been released!!!\n\nChristmas (Hannukah) is a little early this year!\n\nhttps://t.co/HB3ggnspZN\n\n#ASH22 https://t.co/b1V2yZphMh", "conversation_id": "1601300744644472832", "lang": "en", "author_id": "854692626015993857", "id": "1601300744644472832", "entities": {"annotations": [{"start": 8, "end": 20, "probability": 0.6312, "type": "Other", "normalized_text": "ASH Education"}, {"start": 60, "end": 67, "probability": 0.4838, "type": "Person", "normalized_text": "Hannukah"}], "urls": [{"start": 100, "end": 123, "url": "https://t.co/HB3ggnspZN", "expanded_url": "https://ashpublications.org/hematology", "display_url": "ashpublications.org/hematology", "images": [{"url": "https://pbs.twimg.com/news_img/1601300750361333760/cCTjZZww?format=png&name=orig", "width": 520, "height": 675}, {"url": "https://pbs.twimg.com/news_img/1601300750361333760/cCTjZZww?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Hematology | American Society of Hematology", "description": "The Hematology ASH Education Program 2022 provides review articles from the Education Program at the 2022 ASH Annual Meeting. In this publication, each chapter relates to a different session presented at the meeting, spanning the spectrum from basic discovery and disease pathogenesis to the clinical application at the bedside. This activity is supported by educational grants from AstraZeneca; GlaxoSmithKline; Incyte Corp.; Jazz Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; and Novartis Pharmaceuticals", "unwound_url": "https://ashpublications.org/hematology"}, {"start": 132, "end": 155, "url": "https://t.co/b1V2yZphMh", "expanded_url": "https://twitter.com/AaronGoodman33/status/1601300744644472832/photo/1", "display_url": "pic.twitter.com/b1V2yZphMh", "media_key": "3_1601300676432330754"}], "hashtags": [{"start": 125, "end": 131, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1601300744644472832"], "source": "Twitter Web App", "created_at": "2022-12-09T19:40:22.000Z"}, {"text": "@PallawiTorkaMD @RoswellPark @RoswellHemOnc @HemOncFellows @msalmanfaisal Beautiful", "conversation_id": "1601259817154543616", "lang": "en", "author_id": "854692626015993857", "id": "1601299217011847168", "referenced_tweets": [{"type": "replied_to", "id": "1601259817154543616"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "PallawiTorkaMD", "id": "918471705408016384"}, {"start": 16, "end": 28, "username": "RoswellPark", "id": "16044589"}, {"start": 29, "end": 43, "username": "RoswellHemOnc", "id": "1378011784674705409"}, {"start": 44, "end": 58, "username": "HemOncFellows", "id": "1357568654444003335"}, {"start": 59, "end": 73, "username": "msalmanfaisal", "id": "141154688"}]}, "edit_history_tweet_ids": ["1601299217011847168"], "in_reply_to_user_id": "918471705408016384", "source": "Twitter Web App", "created_at": "2022-12-09T19:34:18.000Z"}, {"text": "#ASH22\n\nThese look good!\n\u2066@acweyand\u2069 https://t.co/eVOSM6pkMP", "conversation_id": "1601285083566161922", "lang": "en", "author_id": "854692626015993857", "id": "1601285083566161922", "entities": {"mentions": [{"start": 26, "end": 35, "username": "acweyand", "id": "824315782947631104"}], "annotations": [{"start": 1, "end": 5, "probability": 0.6663, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 37, "end": 60, "url": "https://t.co/eVOSM6pkMP", "expanded_url": "https://twitter.com/AaronGoodman33/status/1601285083566161922/photo/1", "display_url": "pic.twitter.com/eVOSM6pkMP", "media_key": "3_1601285077639602178"}], "hashtags": [{"start": 0, "end": 6, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1601285083566161922"], "source": "Twitter for iPhone", "created_at": "2022-12-09T18:38:09.000Z"}, {"text": "RT @HadidiSamer: Let\u2019s look at 2 smoldering MM trials presented #ASH22 of from different(important) angles #mmsm \ud83e\uddf5\n\nASCENT trial (US)\nGEM-C\u2026", "conversation_id": "1601268229288382465", "lang": "en", "author_id": "854692626015993857", "id": "1601268229288382465", "referenced_tweets": [{"type": "retweeted", "id": "1601170628899323904"}], "entities": {"mentions": [{"start": 3, "end": 15, "username": "HadidiSamer", "id": "774267564"}], "annotations": [{"start": 130, "end": 131, "probability": 0.7554, "type": "Place", "normalized_text": "US"}], "hashtags": [{"start": 64, "end": 70, "tag": "ASH22"}, {"start": 107, "end": 112, "tag": "mmsm"}]}, "edit_history_tweet_ids": ["1601268229288382465"], "source": "Twitter for iPhone", "created_at": "2022-12-09T17:31:10.000Z"}, {"text": "RT @VPrasadMDMPH: So nice to top the impressions \ud83d\ude0a alongside the great @AaronGoodman33\nI will be releasing videos all through #ash22 #ash20\u2026", "conversation_id": "1601119636615221249", "lang": "en", "author_id": "854692626015993857", "id": "1601119636615221249", "referenced_tweets": [{"type": "retweeted", "id": "1601119499625041923"}], "entities": {"mentions": [{"start": 3, "end": 16, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 71, "end": 86, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 127, "end": 131, "probability": 0.5093, "type": "Other", "normalized_text": "ash22"}, {"start": 134, "end": 138, "probability": 0.486, "type": "Other", "normalized_text": "ash20"}], "hashtags": [{"start": 126, "end": 132, "tag": "ash22"}]}, "edit_history_tweet_ids": ["1601119636615221249"], "source": "Twitter for iPhone", "created_at": "2022-12-09T07:40:43.000Z"}, {"text": "RT @ASkarbnik: In real life we\u2019re friends \ud83d\ude09 \n@AaronGoodman33 @GuiperiniMD @matthew_mei @smalveira23 @chadinabhan where are you? https://t.c\u2026", "conversation_id": "1601116932937506816", "lang": "en", "author_id": "854692626015993857", "id": "1601116932937506816", "referenced_tweets": [{"type": "retweeted", "id": "1601115768598712322"}], "entities": {"mentions": [{"start": 3, "end": 13, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 45, "end": 60, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 61, "end": 73, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 74, "end": 86, "username": "matthew_mei", "id": "354168091"}, {"start": 87, "end": 99, "username": "smalveira23", "id": "1125437852836175874"}, {"start": 100, "end": 112, "username": "chadinabhan", "id": "2212735524"}]}, "edit_history_tweet_ids": ["1601116932937506816"], "source": "Twitter for iPhone", "created_at": "2022-12-09T07:29:58.000Z"}, {"text": "@allisonp1979 6 AM to early.  I can do 9 Am same pace ?", "conversation_id": "1601084075368124416", "lang": "en", "author_id": "854692626015993857", "id": "1601109066184798210", "referenced_tweets": [{"type": "replied_to", "id": "1601098351755558913"}], "entities": {"mentions": [{"start": 0, "end": 13, "username": "allisonp1979", "id": "215681001"}]}, "edit_history_tweet_ids": ["1601109066184798210"], "in_reply_to_user_id": "215681001", "source": "Twitter for iPhone", "created_at": "2022-12-09T06:58:43.000Z"}, {"text": "#ASH22\n\nAnyone in New Orleans want to go on a run tomorrow morning?", "conversation_id": "1601084075368124416", "lang": "en", "author_id": "854692626015993857", "id": "1601084075368124416", "edit_history_tweet_ids": ["1601084075368124416"], "entities": {"hashtags": [{"start": 0, "end": 6, "tag": "ASH22"}]}, "source": "Twitter for iPhone", "created_at": "2022-12-09T05:19:24.000Z"}, {"text": "#ASH22\n\nTomorrow At 2 PM excited to learn some pathology and the new classification for blood cancer.  Everyone should come better than soccer. https://t.co/g3Rf86gPJ3", "conversation_id": "1601056656691187712", "lang": "en", "author_id": "854692626015993857", "id": "1601056656691187712", "referenced_tweets": [{"type": "quoted", "id": "1600254596235960320"}], "entities": {"annotations": [{"start": 1, "end": 5, "probability": 0.5083, "type": "Other", "normalized_text": "ASH22"}, {"start": 88, "end": 99, "probability": 0.576, "type": "Other", "normalized_text": "blood cancer"}], "urls": [{"start": 144, "end": 167, "url": "https://t.co/g3Rf86gPJ3", "expanded_url": "https://twitter.com/PapaemmanuilLab/status/1600254596235960320", "display_url": "twitter.com/PapaemmanuilLa\u2026"}], "hashtags": [{"start": 0, "end": 6, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1601056656691187712"], "source": "Twitter for iPhone", "created_at": "2022-12-09T03:30:27.000Z"}, {"text": "@MartinTallman @chadinabhan @romeerizwan @BldCancerDoc @ninashah33 @Mohty_EBMT @JohnPLeonardMD I disagree", "conversation_id": "1601020396685660160", "lang": "en", "author_id": "854692626015993857", "id": "1601054516828606465", "referenced_tweets": [{"type": "replied_to", "id": "1601036828194533377"}], "entities": {"mentions": [{"start": 0, "end": 14, "username": "MartinTallman", "id": "1334487799718961153"}, {"start": 15, "end": 27, "username": "chadinabhan", "id": "2212735524"}, {"start": 28, "end": 40, "username": "romeerizwan", "id": "15622046"}, {"start": 41, "end": 54, "username": "BldCancerDoc", "id": "2809497047"}, {"start": 55, "end": 66, "username": "ninashah33", "id": "1559241414"}, {"start": 67, "end": 78, "username": "Mohty_EBMT", "id": "2626263112"}, {"start": 79, "end": 94, "username": "JohnPLeonardMD", "id": "2891662867"}]}, "edit_history_tweet_ids": ["1601054516828606465"], "in_reply_to_user_id": "1334487799718961153", "source": "Twitter for iPhone", "created_at": "2022-12-09T03:21:57.000Z"}, {"text": "Look who I ran into my two myeloid hero\u2019s!\n\u2066@sanamloghavi\u2069 \n\u2066@PapaemmanuilLab\u2069 \n\n#ASH22 https://t.co/Hrwtu1vjVd", "conversation_id": "1601052343071539200", "lang": "en", "author_id": "854692626015993857", "id": "1601052343071539200", "entities": {"mentions": [{"start": 44, "end": 57, "username": "sanamloghavi", "id": "3076847052"}, {"start": 61, "end": 77, "username": "PapaemmanuilLab", "id": "3154223927"}], "annotations": [{"start": 27, "end": 33, "probability": 0.6896, "type": "Other", "normalized_text": "myeloid"}], "urls": [{"start": 88, "end": 111, "url": "https://t.co/Hrwtu1vjVd", "expanded_url": "https://twitter.com/AaronGoodman33/status/1601052343071539200/photo/1", "display_url": "pic.twitter.com/Hrwtu1vjVd", "media_key": "3_1601052337514201089"}], "hashtags": [{"start": 81, "end": 87, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1601052343071539200"], "source": "Twitter for iPhone", "created_at": "2022-12-09T03:13:19.000Z"}, {"text": "RT @KMirza: &gt;56M impressions #ASH22 and it doesn't even officially start till Saturday! \ud83d\ude4c\ud83c\udffb\ud83d\ude4c\ud83c\udffb\n\nLooking forward to representing #PathAtASH so\u2026", "conversation_id": "1601051473642631175", "lang": "en", "author_id": "854692626015993857", "id": "1601051473642631175", "referenced_tweets": [{"type": "retweeted", "id": "1601008586108174336"}], "entities": {"mentions": [{"start": 3, "end": 10, "username": "KMirza", "id": "28108352"}], "annotations": [{"start": 33, "end": 37, "probability": 0.5661, "type": "Other", "normalized_text": "ASH22"}], "hashtags": [{"start": 32, "end": 38, "tag": "ASH22"}, {"start": 129, "end": 139, "tag": "PathAtASH"}]}, "edit_history_tweet_ids": ["1601051473642631175"], "source": "Twitter for iPhone", "created_at": "2022-12-09T03:09:52.000Z"}, {"text": "@VPrasadMDMPH I think our OncLive abstract would take home gold!", "conversation_id": "1600958272709988352", "lang": "en", "author_id": "854692626015993857", "id": "1601001423864737795", "referenced_tweets": [{"type": "replied_to", "id": "1600958272709988352"}], "entities": {"mentions": [{"start": 0, "end": 13, "username": "VPrasadMDMPH", "id": "1194962714"}], "annotations": [{"start": 26, "end": 32, "probability": 0.7849, "type": "Other", "normalized_text": "OncLive"}]}, "edit_history_tweet_ids": ["1601001423864737795"], "in_reply_to_user_id": "1194962714", "source": "Twitter for iPhone", "created_at": "2022-12-08T23:50:59.000Z"}, {"text": "I\u2019m here!  Great to meet the legendary Dr Evens in person. https://t.co/376FQxGYSb", "conversation_id": "1600982610347720705", "lang": "en", "author_id": "854692626015993857", "id": "1600982610347720705", "referenced_tweets": [{"type": "quoted", "id": "1600982180507049984"}], "entities": {"annotations": [{"start": 39, "end": 46, "probability": 0.435, "type": "Other", "normalized_text": "Dr Evens"}], "urls": [{"start": 59, "end": 82, "url": "https://t.co/376FQxGYSb", "expanded_url": "https://twitter.com/draevens/status/1600982180507049984", "display_url": "twitter.com/draevens/statu\u2026"}]}, "edit_history_tweet_ids": ["1600982610347720705"], "source": "Twitter for iPhone", "created_at": "2022-12-08T22:36:13.000Z"}, {"text": "RT @DrAEvens: @chadinabhan w/ unadulterated man crush on @AaronGoodman33?", "conversation_id": "1600982404508057600", "lang": "en", "author_id": "854692626015993857", "id": "1600982404508057600", "referenced_tweets": [{"type": "retweeted", "id": "1600893983668207617"}], "entities": {"mentions": [{"start": 3, "end": 12, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 14, "end": 26, "username": "chadinabhan", "id": "2212735524"}, {"start": 57, "end": 72, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "edit_history_tweet_ids": ["1600982404508057600"], "source": "Twitter for iPhone", "created_at": "2022-12-08T22:35:24.000Z"}, {"text": "@chadinabhan @montypal @Nirvana @ASkarbnik @sghmd @DocsWhoRock @AleckAmalia @DrRanaMcKay I would say super", "conversation_id": "1600865250374361089", "lang": "en", "author_id": "854692626015993857", "id": "1600981285937127425", "referenced_tweets": [{"type": "replied_to", "id": "1600933603541942272"}], "entities": {"mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 22, "username": "montypal", "id": "24660850"}, {"start": 23, "end": 31, "username": "Nirvana", "id": "68412310"}, {"start": 32, "end": 42, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 43, "end": 49, "username": "sghmd", "id": "53395744"}, {"start": 50, "end": 62, "username": "DocsWhoRock", "id": "1266013486376726528"}, {"start": 63, "end": 75, "username": "AleckAmalia", "id": "1331336294828437504"}, {"start": 76, "end": 88, "username": "DrRanaMcKay", "id": "1113559627809996801"}]}, "edit_history_tweet_ids": ["1600981285937127425"], "in_reply_to_user_id": "2212735524", "source": "Twitter for iPhone", "created_at": "2022-12-08T22:30:58.000Z"}, {"text": "@Haemophage @ASH_hematology I promise to drink them all", "conversation_id": "1600851981702410240", "lang": "en", "author_id": "854692626015993857", "id": "1600953891725529088", "referenced_tweets": [{"type": "replied_to", "id": "1600953322940551168"}], "entities": {"mentions": [{"start": 0, "end": 11, "username": "Haemophage", "id": "149477915"}, {"start": 12, "end": 27, "username": "ASH_hematology", "id": "84072624"}]}, "edit_history_tweet_ids": ["1600953891725529088"], "in_reply_to_user_id": "149477915", "source": "Twitter for iPhone", "created_at": "2022-12-08T20:42:06.000Z"}, {"text": "RT @VPrasadMDMPH: Cure means, after a fixed course of therapy, you have the same survival as age sex matched controls\n\nIt doesn't mean MRD\u2026", "conversation_id": "1600909927718928384", "lang": "en", "author_id": "854692626015993857", "id": "1600909927718928384", "referenced_tweets": [{"type": "retweeted", "id": "1600907726443323392"}], "entities": {"mentions": [{"start": 3, "end": 16, "username": "VPrasadMDMPH", "id": "1194962714"}], "annotations": [{"start": 135, "end": 137, "probability": 0.6784, "type": "Other", "normalized_text": "MRD"}]}, "edit_history_tweet_ids": ["1600909927718928384"], "source": "Twitter for iPhone", "created_at": "2022-12-08T17:47:24.000Z"}, {"text": "@DrAEvens @chadinabhan Jealous?", "conversation_id": "1600893983668207617", "lang": "fr", "author_id": "854692626015993857", "id": "1600900892298907648", "referenced_tweets": [{"type": "replied_to", "id": "1600893983668207617"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 10, "end": 22, "username": "chadinabhan", "id": "2212735524"}]}, "edit_history_tweet_ids": ["1600900892298907648"], "in_reply_to_user_id": "719175246050410496", "source": "Twitter for iPhone", "created_at": "2022-12-08T17:11:30.000Z"}, {"text": "@sghmd I\u2019m hitting the gym when I get there this afternoon!  I\u2019ll need to borrow your protein powder", "conversation_id": "1600882405812113408", "lang": "en", "author_id": "854692626015993857", "id": "1600885699447619584", "referenced_tweets": [{"type": "replied_to", "id": "1600882405812113408"}], "entities": {"mentions": [{"start": 0, "end": 6, "username": "sghmd", "id": "53395744"}]}, "edit_history_tweet_ids": ["1600885699447619584"], "in_reply_to_user_id": "53395744", "source": "Twitter for iPhone", "created_at": "2022-12-08T16:11:08.000Z"}, {"text": "@barttels2 @chadinabhan @Nirvana @ASkarbnik @sghmd @DocsWhoRock @montypal @AleckAmalia @DrRanaMcKay Strong words.  STP music was extremely original.", "conversation_id": "1600865250374361089", "lang": "en", "author_id": "854692626015993857", "id": "1600884532932071426", "referenced_tweets": [{"type": "replied_to", "id": "1600881552837091328"}], "entities": {"mentions": [{"start": 0, "end": 10, "username": "barttels2", "id": "3497730012"}, {"start": 11, "end": 23, "username": "chadinabhan", "id": "2212735524"}, {"start": 24, "end": 32, "username": "Nirvana", "id": "68412310"}, {"start": 33, "end": 43, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 44, "end": 50, "username": "sghmd", "id": "53395744"}, {"start": 51, "end": 63, "username": "DocsWhoRock", "id": "1266013486376726528"}, {"start": 64, "end": 73, "username": "montypal", "id": "24660850"}, {"start": 74, "end": 86, "username": "AleckAmalia", "id": "1331336294828437504"}, {"start": 87, "end": 99, "username": "DrRanaMcKay", "id": "1113559627809996801"}]}, "edit_history_tweet_ids": ["1600884532932071426"], "in_reply_to_user_id": "3497730012", "source": "Twitter for iPhone", "created_at": "2022-12-08T16:06:30.000Z"}, {"text": "RT @ManniMD1: As you prepare for MRD abstracts at #ASH22, here is our paper that explains how MRD has been used in the last 5 years of #mms\u2026", "conversation_id": "1600869365641248775", "lang": "en", "author_id": "854692626015993857", "id": "1600869365641248775", "referenced_tweets": [{"type": "retweeted", "id": "1600868817608925184"}], "entities": {"mentions": [{"start": 3, "end": 12, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 33, "end": 35, "probability": 0.5955, "type": "Other", "normalized_text": "MRD"}, {"start": 51, "end": 55, "probability": 0.6588, "type": "Other", "normalized_text": "ASH22"}, {"start": 94, "end": 96, "probability": 0.6378, "type": "Other", "normalized_text": "MRD"}], "hashtags": [{"start": 50, "end": 56, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1600869365641248775"], "source": "Twitter for iPhone", "created_at": "2022-12-08T15:06:14.000Z"}, {"text": "RT @chadinabhan: The #HealthcareUnfiltered podcast crashed the party at PAPA @AaronGoodman33 house 2 talk guitar and @Nirvana \nThere was NO\u2026", "conversation_id": "1600866504295084032", "lang": "en", "author_id": "854692626015993857", "id": "1600866504295084032", "referenced_tweets": [{"type": "retweeted", "id": "1600865250374361089"}], "entities": {"mentions": [{"start": 3, "end": 15, "username": "chadinabhan", "id": "2212735524"}, {"start": 77, "end": 92, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 117, "end": 125, "username": "Nirvana", "id": "68412310"}], "annotations": [{"start": 72, "end": 75, "probability": 0.4123, "type": "Organization", "normalized_text": "PAPA"}], "hashtags": [{"start": 21, "end": 42, "tag": "HealthcareUnfiltered"}]}, "edit_history_tweet_ids": ["1600866504295084032"], "source": "Twitter for iPhone", "created_at": "2022-12-08T14:54:51.000Z"}, {"text": "@Dr_AmerZeidan awesome", "conversation_id": "1600850247185354752", "lang": "en", "author_id": "854692626015993857", "id": "1600854504865341440", "referenced_tweets": [{"type": "replied_to", "id": "1600854069664366592"}], "entities": {"mentions": [{"start": 0, "end": 14, "username": "Dr_AmerZeidan", "id": "1144997352148787201"}]}, "edit_history_tweet_ids": ["1600854504865341440"], "in_reply_to_user_id": "1144997352148787201", "source": "Twitter Web App", "created_at": "2022-12-08T14:07:11.000Z"}, {"text": "#ASH22 \n\n@ASH_hematology has 2 hours to release the ASH Education book before I board my plane to New Orleans.\n\nAnyone in New Orleans tonight want to get a beer and talk hematology DM me. https://t.co/IoYWmTnGp6", "conversation_id": "1600851981702410240", "lang": "en", "author_id": "854692626015993857", "id": "1600851981702410240", "entities": {"mentions": [{"start": 9, "end": 24, "username": "ASH_hematology", "id": "84072624"}], "annotations": [{"start": 52, "end": 64, "probability": 0.6663, "type": "Other", "normalized_text": "ASH Education"}, {"start": 98, "end": 108, "probability": 0.9897, "type": "Place", "normalized_text": "New Orleans"}, {"start": 122, "end": 132, "probability": 0.9898, "type": "Place", "normalized_text": "New Orleans"}], "urls": [{"start": 188, "end": 211, "url": "https://t.co/IoYWmTnGp6", "expanded_url": "https://twitter.com/AaronGoodman33/status/1600851981702410240/photo/1", "display_url": "pic.twitter.com/IoYWmTnGp6", "media_key": "3_1600851694492991488"}], "hashtags": [{"start": 0, "end": 6, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1600851981702410240"], "source": "Twitter Web App", "created_at": "2022-12-08T13:57:09.000Z"}, {"text": "An unusual cause of splenomegaly and pancytopenia  in an adult!\n\nThink back to chemistry class and look at that femur...\n\nI have seen a few of these so yes you need to know it.  And yes this can present in adults!\n\nhttps://t.co/ahkx3EXP79 https://t.co/Kj7amRys98", "conversation_id": "1600850247185354752", "lang": "en", "author_id": "854692626015993857", "id": "1600850247185354752", "entities": {"annotations": [{"start": 20, "end": 31, "probability": 0.5439, "type": "Other", "normalized_text": "splenomegaly"}, {"start": 37, "end": 48, "probability": 0.5797, "type": "Other", "normalized_text": "pancytopenia"}], "urls": [{"start": 215, "end": 238, "url": "https://t.co/ahkx3EXP79", "expanded_url": "https://tinyurl.com/mrxjmfcx", "display_url": "tinyurl.com/mrxjmfcx", "images": [{"url": "https://pbs.twimg.com/news_img/1600850252679913473/WC5zZrIZ?format=jpg&name=orig", "width": 1200, "height": 630}, {"url": "https://pbs.twimg.com/news_img/1600850252679913473/WC5zZrIZ?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Quantifying the Erlenmeyer flask deformity. | Semantic Scholar", "description": "Unlike diagnostic assignments based on subjective review, this simple procedure for identifying the modelling deformity is based on robust quantitative measurement and should facilitate comparative studies between different groups of patients, and may allow more rigorous exploration of the pathogenesis of the complex osseous manifestations of Gaucher's disease to be undertaken. OBJECTIVE Erlenmeyer flask deformity is a common radiological finding in patients with Gaucher's disease; however, no definition of this deformity exists and the reported prevalence of the deformity varies widely. To devise an easily applied definition of this deformity, we investigated a cohort of knee radiographs in which there was consensus between three experienced radiologists as to the presence or absence of Erlenmeyer flask morphology. METHODS Using the presence or absence of Erlenmeyer flask morphology as a benchmark, we measured the diameter of the femur at the level of the physeal scar and serially at ", "unwound_url": "https://www.semanticscholar.org/paper/Quantifying-the-Erlenmeyer-flask-deformity.-Carter-Rajan/122771e4483466e411ef812b8344761f1109aad1"}, {"start": 239, "end": 262, "url": "https://t.co/Kj7amRys98", "expanded_url": "https://twitter.com/AaronGoodman33/status/1600850247185354752/photo/1", "display_url": "pic.twitter.com/Kj7amRys98", "media_key": "3_1600850110845427712"}]}, "edit_history_tweet_ids": ["1600850247185354752"], "source": "Twitter Web App", "created_at": "2022-12-08T13:50:15.000Z"}, {"text": "@ManniMD1 @HiraSMian Epic in box empty no more clinic.   Don\u2019t be jealous.", "conversation_id": "1600685500339171330", "lang": "en", "author_id": "854692626015993857", "id": "1600697417061781504", "referenced_tweets": [{"type": "replied_to", "id": "1600695160878223360"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 20, "username": "HiraSMian", "id": "419595308"}]}, "edit_history_tweet_ids": ["1600697417061781504"], "in_reply_to_user_id": "1269642863924609025", "source": "Twitter for iPhone", "created_at": "2022-12-08T03:42:58.000Z"}, {"text": "@VPrasadMDMPH @MichaelJSlade @CyclingDoctor @LabFehniger @DiPersioLab @ManniMD1 @DavidSteensma @bdermanmd @VincentRK @myelomaMD @Geoff_Uy Obviously", "conversation_id": "1600642889280798721", "lang": "en", "author_id": "854692626015993857", "id": "1600694917885743104", "referenced_tweets": [{"type": "replied_to", "id": "1600694442427502594"}], "entities": {"mentions": [{"start": 0, "end": 13, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 14, "end": 28, "username": "MichaelJSlade", "id": "626650397"}, {"start": 29, "end": 43, "username": "CyclingDoctor", "id": "23036480"}, {"start": 44, "end": 56, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 57, "end": 69, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 70, "end": 79, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 80, "end": 94, "username": "DavidSteensma", "id": "2739065578"}, {"start": 95, "end": 105, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 106, "end": 116, "username": "VincentRK", "id": "24261916"}, {"start": 117, "end": 127, "username": "myelomaMD", "id": "301568235"}, {"start": 128, "end": 137, "username": "Geoff_Uy", "id": "985139345928736768"}]}, "edit_history_tweet_ids": ["1600694917885743104"], "in_reply_to_user_id": "1194962714", "source": "Twitter for iPhone", "created_at": "2022-12-08T03:33:02.000Z"}, {"text": "@MichaelJSlade @CyclingDoctor @LabFehniger @DiPersioLab @ManniMD1 @DavidSteensma @bdermanmd @VPrasadMDMPH @VincentRK @myelomaMD @Geoff_Uy For main heme malignancies i go through the clinical results categories for oral abstracts and read ones that stand out/may alter practice.\n\nFor clinical interests (t cell/skin lymphoma, histiocytosis) I review all oral abstracts (usually not many).\n\nLeave it to Twitter for rest!", "conversation_id": "1600642889280798721", "lang": "en", "author_id": "854692626015993857", "id": "1600690511395758081", "referenced_tweets": [{"type": "replied_to", "id": "1600642889280798721"}], "entities": {"mentions": [{"start": 0, "end": 14, "username": "MichaelJSlade", "id": "626650397"}, {"start": 15, "end": 29, "username": "CyclingDoctor", "id": "23036480"}, {"start": 30, "end": 42, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 43, "end": 55, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 56, "end": 65, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 66, "end": 80, "username": "DavidSteensma", "id": "2739065578"}, {"start": 81, "end": 91, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 92, "end": 105, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 106, "end": 116, "username": "VincentRK", "id": "24261916"}, {"start": 117, "end": 127, "username": "myelomaMD", "id": "301568235"}, {"start": 128, "end": 137, "username": "Geoff_Uy", "id": "985139345928736768"}], "annotations": [{"start": 325, "end": 337, "probability": 0.6394, "type": "Other", "normalized_text": "histiocytosis"}, {"start": 401, "end": 407, "probability": 0.9501, "type": "Other", "normalized_text": "Twitter"}]}, "edit_history_tweet_ids": ["1600690511395758081"], "in_reply_to_user_id": "626650397", "source": "Twitter for iPhone", "created_at": "2022-12-08T03:15:31.000Z"}, {"text": "@JReinerMD Yes mask at the meeting but take off at the after party at the bar.", "conversation_id": "1600655843313213440", "lang": "en", "author_id": "854692626015993857", "id": "1600673506965868544", "referenced_tweets": [{"type": "replied_to", "id": "1600655843313213440"}], "entities": {"mentions": [{"start": 0, "end": 10, "username": "JReinerMD", "id": "537795028"}]}, "edit_history_tweet_ids": ["1600673506965868544"], "in_reply_to_user_id": "537795028", "source": "Twitter Web App", "created_at": "2022-12-08T02:07:57.000Z"}, {"text": "@JKanerMD @Dr_AmerZeidan The 60 vs 90 question was never answered definitively in my opinion. I much prefer these studies then numerous redundant phase 2 studies that usually don\u2019t even reinforce my practice.  Both of you I look forward to seeing at ASH", "conversation_id": "1600519646028869633", "lang": "en", "author_id": "854692626015993857", "id": "1600654832171294721", "referenced_tweets": [{"type": "replied_to", "id": "1600617014053183491"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "JKanerMD", "id": "782764410"}, {"start": 10, "end": 24, "username": "Dr_AmerZeidan", "id": "1144997352148787201"}], "annotations": [{"start": 250, "end": 252, "probability": 0.3819, "type": "Organization", "normalized_text": "ASH"}]}, "edit_history_tweet_ids": ["1600654832171294721"], "in_reply_to_user_id": "782764410", "source": "Twitter for iPhone", "created_at": "2022-12-08T00:53:45.000Z"}, {"text": "@ManniMD1 @iStopMM @sykristinsson can you send me the talk?", "conversation_id": "1600545405540126720", "lang": "en", "author_id": "854692626015993857", "id": "1600546340873781248", "referenced_tweets": [{"type": "replied_to", "id": "1600545405540126720"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 18, "username": "iStopMM", "id": "844232399319941122"}, {"start": 19, "end": 33, "username": "sykristinsson", "id": "3078258341"}]}, "edit_history_tweet_ids": ["1600546340873781248"], "in_reply_to_user_id": "1269642863924609025", "source": "Twitter Web App", "created_at": "2022-12-07T17:42:39.000Z"}, {"text": "#ASH22 Practice Changers\n\nAmazing study by team leukemia!\n\n2 questions in 1 trial!\n\nNewly diagnosed AML fit patients\n\nInduction daunorubicin 90 mg/m2 = 60 mg/m2!\n\nA 2nd induction with anthracycline not needed in responders.\n\nDaunorubicin dose = 60 mg/m2!\n\nhttps://t.co/pQ1sZbIV0g https://t.co/jeBqaap1mG https://t.co/FLIlPqnyjy", "conversation_id": "1600519646028869633", "lang": "en", "author_id": "854692626015993857", "id": "1600519646028869633", "referenced_tweets": [{"type": "quoted", "id": "1600261398268764160"}], "entities": {"annotations": [{"start": 1, "end": 5, "probability": 0.5809, "type": "Other", "normalized_text": "ASH22"}, {"start": 48, "end": 55, "probability": 0.7452, "type": "Other", "normalized_text": "leukemia"}, {"start": 100, "end": 102, "probability": 0.385, "type": "Other", "normalized_text": "AML"}, {"start": 128, "end": 139, "probability": 0.6058, "type": "Other", "normalized_text": "daunorubicin"}, {"start": 225, "end": 236, "probability": 0.7264, "type": "Other", "normalized_text": "Daunorubicin"}], "urls": [{"start": 256, "end": 279, "url": "https://t.co/pQ1sZbIV0g", "expanded_url": "https://tinyurl.com/bdcm7u8t", "display_url": "tinyurl.com/bdcm7u8t", "status": 200, "title": "Paper: Single Versus Double Induction with \u201c7+3\u201d Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: New Approaches to Combination Chemotherapy and Venetoclax Plus Hypomethylating Agent Therapy in AML Hematology Disease Topics & Pathways: adult, Clinical Practice (Health Services and Quality), Combination therapy, Therapies, therapy sequence, Study Population, Human Christoph R\u00f6llig, MD, MSC 1 *, Bj\u00f6rn Steffen, MD 2 *, Christoph", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper157126.html"}, {"start": 280, "end": 303, "url": "https://t.co/jeBqaap1mG", "expanded_url": "https://twitter.com/AaronGoodman33/status/1600519646028869633/photo/1", "display_url": "pic.twitter.com/jeBqaap1mG", "media_key": "3_1600519187624927232"}, {"start": 304, "end": 327, "url": "https://t.co/FLIlPqnyjy", "expanded_url": "https://twitter.com/AaronGoodman33/status/1600261398268764160", "display_url": "twitter.com/AaronGoodman33\u2026"}], "hashtags": [{"start": 0, "end": 6, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1600519646028869633"], "source": "Twitter Web App", "created_at": "2022-12-07T15:56:34.000Z"}, {"text": "@ManniMD1 well that's because they didn't use isatuximab", "conversation_id": "1600478408659517440", "lang": "en", "author_id": "854692626015993857", "id": "1600515070924316675", "referenced_tweets": [{"type": "replied_to", "id": "1600478408659517440"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 46, "end": 55, "probability": 0.8072, "type": "Other", "normalized_text": "isatuximab"}]}, "edit_history_tweet_ids": ["1600515070924316675"], "in_reply_to_user_id": "1269642863924609025", "source": "Twitter Web App", "created_at": "2022-12-07T15:38:23.000Z"}, {"text": "#ASH22 \n\nIs anyone as eager as me for the release of the ASH 2022 Education Book!?\n\nHopefully they bring back the print edition as I always enjoyed reading it on my trip home and then cover to cover when I got home. https://t.co/MzdOs6IcYM", "conversation_id": "1600512579306016768", "lang": "en", "author_id": "854692626015993857", "id": "1600512579306016768", "entities": {"annotations": [{"start": 1, "end": 5, "probability": 0.5727, "type": "Other", "normalized_text": "ASH22"}, {"start": 57, "end": 64, "probability": 0.6676, "type": "Other", "normalized_text": "ASH 2022"}], "urls": [{"start": 216, "end": 239, "url": "https://t.co/MzdOs6IcYM", "expanded_url": "https://twitter.com/AaronGoodman33/status/1600512579306016768/photo/1", "display_url": "pic.twitter.com/MzdOs6IcYM", "media_key": "3_1600512549727793152"}], "hashtags": [{"start": 0, "end": 6, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1600512579306016768"], "source": "Twitter Web App", "created_at": "2022-12-07T15:28:29.000Z"}, {"text": "@chadinabhan @BloodAdvances @ASkarbnik @GuiperiniMD Whatever @ASkarbnik says I\u2019ll do the opposite.", "conversation_id": "1600467379158294528", "lang": "en", "author_id": "854692626015993857", "id": "1600509053347966977", "referenced_tweets": [{"type": "replied_to", "id": "1600467379158294528"}], "entities": {"mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 27, "username": "BloodAdvances", "id": "732570175162179585"}, {"start": 28, "end": 38, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 39, "end": 51, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 61, "end": 71, "username": "ASkarbnik", "id": "999010996034338818"}]}, "edit_history_tweet_ids": ["1600509053347966977"], "in_reply_to_user_id": "2212735524", "source": "Twitter for iPhone", "created_at": "2022-12-07T15:14:28.000Z"}, {"text": "RT @marklewismd: Of the many miseries endured by patients  in the hospital one of them is the needlessly restrictive diet \ud83d\udc47\ud83c\udffb p.o. &gt; ANC", "conversation_id": "1600327580909211648", "lang": "en", "author_id": "854692626015993857", "id": "1600327580909211648", "referenced_tweets": [{"type": "retweeted", "id": "1600283901821583360"}], "entities": {"mentions": [{"start": 3, "end": 15, "username": "marklewismd", "id": "807337182"}], "annotations": [{"start": 135, "end": 137, "probability": 0.8599, "type": "Organization", "normalized_text": "ANC"}]}, "edit_history_tweet_ids": ["1600327580909211648"], "source": "Twitter Web App", "created_at": "2022-12-07T03:13:22.000Z"}, {"text": "@ManniMD1 Not that I do much allo for myeloma. I do for primary plasma cell leukemia in young patient who understands the risks.", "conversation_id": "1600320621426397184", "lang": "en", "author_id": "854692626015993857", "id": "1600321311385219072", "referenced_tweets": [{"type": "replied_to", "id": "1600321063426326528"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 38, "end": 44, "probability": 0.763, "type": "Other", "normalized_text": "myeloma"}, {"start": 76, "end": 83, "probability": 0.392, "type": "Other", "normalized_text": "leukemia"}]}, "edit_history_tweet_ids": ["1600321311385219072"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for iPhone", "created_at": "2022-12-07T02:48:27.000Z"}, {"text": "@ManniMD1 But perhaps the only true cure?", "conversation_id": "1600320621426397184", "lang": "en", "author_id": "854692626015993857", "id": "1600321063426326528", "referenced_tweets": [{"type": "replied_to", "id": "1600320621426397184"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}]}, "edit_history_tweet_ids": ["1600321063426326528"], "in_reply_to_user_id": "1269642863924609025", "source": "Twitter for iPhone", "created_at": "2022-12-07T02:47:28.000Z"}, {"text": "@acweyand @AleckAmalia I can\u2019t spell.  \u201cThere\u201d", "conversation_id": "1600313165601857539", "lang": "en", "author_id": "854692626015993857", "id": "1600320539385507840", "referenced_tweets": [{"type": "replied_to", "id": "1600320182240522240"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "acweyand", "id": "824315782947631104"}, {"start": 10, "end": 22, "username": "AleckAmalia", "id": "1331336294828437504"}]}, "edit_history_tweet_ids": ["1600320539385507840"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for iPhone", "created_at": "2022-12-07T02:45:23.000Z"}, {"text": "@acweyand Per @AleckAmalia Cafe Du Monde.  I will be going their daily.", "conversation_id": "1600313165601857539", "lang": "en", "author_id": "854692626015993857", "id": "1600320182240522240", "referenced_tweets": [{"type": "replied_to", "id": "1600313165601857539"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "acweyand", "id": "824315782947631104"}, {"start": 14, "end": 26, "username": "AleckAmalia", "id": "1331336294828437504"}], "annotations": [{"start": 27, "end": 39, "probability": 0.877, "type": "Other", "normalized_text": "Cafe Du Monde"}]}, "edit_history_tweet_ids": ["1600320182240522240"], "in_reply_to_user_id": "824315782947631104", "source": "Twitter for iPhone", "created_at": "2022-12-07T02:43:58.000Z"}, {"text": "@dgermain21 @PapaemmanuilLab @ash22 Look forward to meeting you in person my friend!", "conversation_id": "1600254596235960320", "lang": "en", "author_id": "854692626015993857", "id": "1600297470130806787", "referenced_tweets": [{"type": "replied_to", "id": "1600297330946678784"}], "entities": {"mentions": [{"start": 0, "end": 11, "username": "dgermain21", "id": "18821994"}, {"start": 12, "end": 28, "username": "PapaemmanuilLab", "id": "3154223927"}, {"start": 29, "end": 35, "username": "ash22", "id": "18618457"}]}, "edit_history_tweet_ids": ["1600297470130806787"], "in_reply_to_user_id": "18821994", "source": "Twitter for iPhone", "created_at": "2022-12-07T01:13:43.000Z"}, {"text": "@Abdallah81MD Solid plan", "conversation_id": "1600296085209202688", "lang": "en", "author_id": "854692626015993857", "id": "1600297236516130816", "referenced_tweets": [{"type": "replied_to", "id": "1600296085209202688"}], "entities": {"mentions": [{"start": 0, "end": 13, "username": "Abdallah81MD", "id": "1026947037080772610"}]}, "edit_history_tweet_ids": ["1600297236516130816"], "in_reply_to_user_id": "1026947037080772610", "source": "Twitter for iPhone", "created_at": "2022-12-07T01:12:47.000Z"}, {"text": "@PapaemmanuilLab @ash22 I\u2019ll be there!", "conversation_id": "1600254596235960320", "lang": "en", "author_id": "854692626015993857", "id": "1600296136417619968", "referenced_tweets": [{"type": "replied_to", "id": "1600254596235960320"}], "entities": {"mentions": [{"start": 0, "end": 16, "username": "PapaemmanuilLab", "id": "3154223927"}, {"start": 17, "end": 23, "username": "ash22", "id": "18618457"}]}, "edit_history_tweet_ids": ["1600296136417619968"], "in_reply_to_user_id": "3154223927", "source": "Twitter for iPhone", "created_at": "2022-12-07T01:08:25.000Z"}, {"text": "#ASH22 Practice Changers\n\nTime to abolish for good the neutropenic diet!\nLet patients with cancer eat what ever they want even if neutropenic.\n\nRCT in HSCT or induction chemo pts\nRandomized 1:1 to standard diet or protective diet.\n\nNo difference in infections! https://t.co/sKNJ3DN7sU https://t.co/ewKqTmAQ1u", "conversation_id": "1600261398268764160", "lang": "en", "author_id": "854692626015993857", "id": "1600261398268764160", "referenced_tweets": [{"type": "quoted", "id": "1599925397139099648"}], "entities": {"annotations": [{"start": 1, "end": 5, "probability": 0.6249, "type": "Other", "normalized_text": "ASH22"}, {"start": 151, "end": 154, "probability": 0.7166, "type": "Other", "normalized_text": "HSCT"}], "urls": [{"start": 261, "end": 284, "url": "https://t.co/sKNJ3DN7sU", "expanded_url": "https://twitter.com/AaronGoodman33/status/1600261398268764160/photo/1", "display_url": "pic.twitter.com/sKNJ3DN7sU", "media_key": "3_1600260629113077760"}, {"start": 285, "end": 308, "url": "https://t.co/ewKqTmAQ1u", "expanded_url": "https://twitter.com/AaronGoodman33/status/1599925397139099648", "display_url": "twitter.com/AaronGoodman33\u2026"}], "hashtags": [{"start": 0, "end": 6, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1600261398268764160"], "source": "Twitter Web App", "created_at": "2022-12-06T22:50:23.000Z"}, {"text": "@ASkarbnik @matthew_mei @GuiperiniMD @paulocruzphi If we are discussing best Beatles albums the order is as following \n\n1. White album\n2. Revolver\n3. Sgt Peppers\n4. Abbey Road\n5. Rubber soul\n6. Magical mystery tour\n7. Let it Be\n8. Beatles for sale\n9. With the Beatles", "conversation_id": "1599065279786409985", "lang": "en", "author_id": "854692626015993857", "id": "1600245303760023552", "referenced_tweets": [{"type": "replied_to", "id": "1600202096393224193"}], "entities": {"mentions": [{"start": 0, "end": 10, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 11, "end": 23, "username": "matthew_mei", "id": "354168091"}, {"start": 24, "end": 36, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 37, "end": 50, "username": "paulocruzphi", "id": "1913011345"}], "annotations": [{"start": 77, "end": 83, "probability": 0.9859, "type": "Organization", "normalized_text": "Beatles"}, {"start": 123, "end": 133, "probability": 0.6495, "type": "Other", "normalized_text": "White album"}, {"start": 138, "end": 145, "probability": 0.714, "type": "Other", "normalized_text": "Revolver"}, {"start": 150, "end": 160, "probability": 0.6923, "type": "Other", "normalized_text": "Sgt Peppers"}, {"start": 165, "end": 174, "probability": 0.8863, "type": "Other", "normalized_text": "Abbey Road"}, {"start": 179, "end": 189, "probability": 0.8885, "type": "Other", "normalized_text": "Rubber soul"}, {"start": 194, "end": 213, "probability": 0.9177, "type": "Other", "normalized_text": "Magical mystery tour"}, {"start": 218, "end": 226, "probability": 0.9697, "type": "Other", "normalized_text": "Let it Be"}, {"start": 231, "end": 246, "probability": 0.7139, "type": "Organization", "normalized_text": "Beatles for sale"}, {"start": 251, "end": 258, "probability": 0.518, "type": "Other", "normalized_text": "With the"}, {"start": 260, "end": 266, "probability": 0.7233, "type": "Organization", "normalized_text": "Beatles"}]}, "edit_history_tweet_ids": ["1600245303760023552"], "in_reply_to_user_id": "999010996034338818", "source": "Twitter for iPhone", "created_at": "2022-12-06T21:46:26.000Z"}, {"text": "Perils of Ignoring Overall Survival in Interpreting the Myeloma Literature - PubMed\n\n\u2066@ManniMD1\u2069 \n\u2066@drkevinknopf\u2069  https://t.co/kfx3VK1WJs", "conversation_id": "1600165250346541056", "lang": "en", "author_id": "854692626015993857", "id": "1600165250346541056", "entities": {"mentions": [{"start": 86, "end": 95, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 99, "end": 112, "username": "drkevinknopf", "id": "1084451400"}], "annotations": [{"start": 56, "end": 73, "probability": 0.7236, "type": "Other", "normalized_text": "Myeloma Literature"}], "urls": [{"start": 115, "end": 138, "url": "https://t.co/kfx3VK1WJs", "expanded_url": "https://pubmed.ncbi.nlm.nih.gov/34652953/", "display_url": "pubmed.ncbi.nlm.nih.gov/34652953/", "images": [{"url": "https://pbs.twimg.com/news_img/1600165251340652550/EMGpTkfM?format=jpg&name=orig", "width": 1200, "height": 1200}, {"url": "https://pbs.twimg.com/news_img/1600165251340652550/EMGpTkfM?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Perils of Ignoring Overall Survival in Interpreting the Myeloma Literature - PubMed", "description": "Perils of Ignoring Overall Survival in Interpreting the Myeloma Literature", "unwound_url": "https://pubmed.ncbi.nlm.nih.gov/34652953/"}]}, "edit_history_tweet_ids": ["1600165250346541056"], "source": "Twitter for iPhone", "created_at": "2022-12-06T16:28:19.000Z"}, {"text": "@matthew_mei @ASkarbnik @GuiperiniMD I\u2019ll be there Thursday through Monday.  Text me when you get in", "conversation_id": "1599925397139099648", "lang": "en", "author_id": "854692626015993857", "id": "1599950096439054336", "referenced_tweets": [{"type": "replied_to", "id": "1599947443327893504"}], "entities": {"mentions": [{"start": 0, "end": 12, "username": "matthew_mei", "id": "354168091"}, {"start": 13, "end": 23, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 24, "end": 36, "username": "GuiperiniMD", "id": "1294745239656202240"}]}, "edit_history_tweet_ids": ["1599950096439054336"], "in_reply_to_user_id": "354168091", "source": "Twitter for iPhone", "created_at": "2022-12-06T02:13:23.000Z"}, {"text": "@matthew_mei @GuiperiniMD @ASkarbnik Triangle you take a pill and you might not need auto and expect similar remission.   SHINE you take a pill and delay time to taking pill without removing other therapy.  3 vs 2 like a myeloma trial.", "conversation_id": "1599925397139099648", "lang": "en", "author_id": "854692626015993857", "id": "1599943208800497664", "referenced_tweets": [{"type": "replied_to", "id": "1599942610046824449"}], "entities": {"mentions": [{"start": 0, "end": 12, "username": "matthew_mei", "id": "354168091"}, {"start": 13, "end": 25, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 26, "end": 36, "username": "ASkarbnik", "id": "999010996034338818"}], "annotations": [{"start": 37, "end": 44, "probability": 0.4808, "type": "Other", "normalized_text": "Triangle"}, {"start": 221, "end": 227, "probability": 0.6526, "type": "Other", "normalized_text": "myeloma"}]}, "edit_history_tweet_ids": ["1599943208800497664"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for iPhone", "created_at": "2022-12-06T01:46:01.000Z"}, {"text": "@matthew_mei @GuiperiniMD @ASkarbnik This study gets rid of one toxic therapy (auto) and replaces with something else.  SHINE just adds therapy we know works.\n\nNeither are truly practice changing if you read my attached tweet although this study better than SHINE which just confirmed the obvious.", "conversation_id": "1599925397139099648", "lang": "en", "author_id": "854692626015993857", "id": "1599942610046824449", "referenced_tweets": [{"type": "replied_to", "id": "1599941573659463680"}], "entities": {"mentions": [{"start": 0, "end": 12, "username": "matthew_mei", "id": "354168091"}, {"start": 13, "end": 25, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 26, "end": 36, "username": "ASkarbnik", "id": "999010996034338818"}], "annotations": [{"start": 258, "end": 262, "probability": 0.7584, "type": "Other", "normalized_text": "SHINE"}]}, "edit_history_tweet_ids": ["1599942610046824449"], "in_reply_to_user_id": "354168091", "source": "Twitter for iPhone", "created_at": "2022-12-06T01:43:38.000Z"}, {"text": "@davideyoungmd I do not use HyperCVAD for MCL\n\nLAtely I have been using BR alternating with R-HiDAC or just BR on its own", "conversation_id": "1599925397139099648", "lang": "en", "author_id": "854692626015993857", "id": "1599933239589998592", "referenced_tweets": [{"type": "replied_to", "id": "1599930810962182144"}], "entities": {"mentions": [{"start": 0, "end": 14, "username": "davideyoungmd", "id": "2170420038"}], "annotations": [{"start": 28, "end": 36, "probability": 0.8487, "type": "Other", "normalized_text": "HyperCVAD"}, {"start": 42, "end": 52, "probability": 0.6262, "type": "Other", "normalized_text": "MCL\n\nLAtely"}, {"start": 92, "end": 98, "probability": 0.7376, "type": "Other", "normalized_text": "R-HiDAC"}]}, "edit_history_tweet_ids": ["1599933239589998592"], "in_reply_to_user_id": "2170420038", "source": "Twitter Web App", "created_at": "2022-12-06T01:06:24.000Z"}, {"text": "@matthew_mei Did you know in SHINE ibrutinib maintenance delayed time to starting ibrutinib.", "conversation_id": "1599925397139099648", "lang": "en", "author_id": "854692626015993857", "id": "1599930678090792960", "referenced_tweets": [{"type": "replied_to", "id": "1599929906628284416"}], "entities": {"mentions": [{"start": 0, "end": 12, "username": "matthew_mei", "id": "354168091"}], "annotations": [{"start": 29, "end": 43, "probability": 0.6669, "type": "Other", "normalized_text": "SHINE ibrutinib"}, {"start": 82, "end": 90, "probability": 0.7194, "type": "Other", "normalized_text": "ibrutinib"}]}, "edit_history_tweet_ids": ["1599930678090792960"], "in_reply_to_user_id": "354168091", "source": "Twitter for iPhone", "created_at": "2022-12-06T00:56:13.000Z"}, {"text": "RT @AaronGoodman33: I will be sharing over next few days #ASH22 abstracts that are practice changing for me! \n\nBMTCTN 1703 by legendary bas\u2026", "conversation_id": "1599927311125843968", "lang": "en", "author_id": "854692626015993857", "id": "1599927311125843968", "referenced_tweets": [{"type": "retweeted", "id": "1598728138812710912"}], "entities": {"mentions": [{"start": 3, "end": 18, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 58, "end": 62, "probability": 0.6569, "type": "Other", "normalized_text": "ASH22"}, {"start": 111, "end": 116, "probability": 0.7636, "type": "Other", "normalized_text": "BMTCTN"}], "hashtags": [{"start": 57, "end": 63, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1599927311125843968"], "source": "Twitter for iPhone", "created_at": "2022-12-06T00:42:50.000Z"}, {"text": "RT @AaronGoodman33: #ASH22 Practice Changers\n\nE1910 @MartinTallman\n\nPh- B-ALL (30-70 yo) \nBFM-like induction [PEG if&lt;55 yo,ritux if CD20+]\u2026", "conversation_id": "1599927267500912640", "lang": "en", "author_id": "854692626015993857", "id": "1599927267500912640", "referenced_tweets": [{"type": "retweeted", "id": "1599093726345056256"}], "entities": {"mentions": [{"start": 3, "end": 18, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 52, "end": 66, "username": "MartinTallman", "id": "1334487799718961153"}], "hashtags": [{"start": 20, "end": 26, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1599927267500912640"], "source": "Twitter for iPhone", "created_at": "2022-12-06T00:42:40.000Z"}, {"text": "RT @ManniMD1: #ASH22 starts this week.\n\nHere is a list of top 10 abstracts that have already influenced my thought and practice in myeloma!\u2026", "conversation_id": "1599926967360720897", "lang": "en", "author_id": "854692626015993857", "id": "1599926967360720897", "referenced_tweets": [{"type": "retweeted", "id": "1599779550753193985"}], "entities": {"mentions": [{"start": 3, "end": 12, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 15, "end": 19, "probability": 0.6877, "type": "Other", "normalized_text": "ASH22"}, {"start": 131, "end": 137, "probability": 0.7355, "type": "Other", "normalized_text": "myeloma"}], "hashtags": [{"start": 14, "end": 20, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1599926967360720897"], "source": "Twitter for iPhone", "created_at": "2022-12-06T00:41:28.000Z"}, {"text": "I do not know if this will change my practice as ibrutinib maintenance is no walk in park, but will have long discussion with patient about approaches.\n\nAlso FFS not best endpoint, and OS all the same, but its good to know ASCT can be omitted.", "conversation_id": "1599925397139099648", "lang": "en", "author_id": "854692626015993857", "id": "1599926111143866368", "referenced_tweets": [{"type": "replied_to", "id": "1599925397139099648"}], "entities": {"annotations": [{"start": 49, "end": 57, "probability": 0.5657, "type": "Other", "normalized_text": "ibrutinib"}, {"start": 158, "end": 160, "probability": 0.3926, "type": "Organization", "normalized_text": "FFS"}, {"start": 185, "end": 186, "probability": 0.5433, "type": "Other", "normalized_text": "OS"}, {"start": 223, "end": 226, "probability": 0.5962, "type": "Other", "normalized_text": "ASCT"}]}, "edit_history_tweet_ids": ["1599926111143866368"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter Web App", "created_at": "2022-12-06T00:38:04.000Z"}, {"text": "#ASH22 Practice Changers\n\nTriangle study!\n\nFrontline Mantle Cell\nTransplant eligible\n\n3 arms*\nRCHOP/DHAP + ibrutinib-&gt;I maint\nRCHOP/DHAP + I-&gt;ASCT-&gt;I maint\nRCHOP/DHAP-&gt;ASCT\n*ritux maint allowed\n\nFFS equal in ibrutinib arms regardless of ASCT or not\n\nCan \ud83d\udeabASCT if ibrutinib used https://t.co/btoPwYi8KK https://t.co/pG7exZwa7f", "conversation_id": "1599925397139099648", "lang": "en", "author_id": "854692626015993857", "id": "1599925397139099648", "referenced_tweets": [{"type": "quoted", "id": "1599093726345056256"}], "entities": {"annotations": [{"start": 53, "end": 63, "probability": 0.5267, "type": "Other", "normalized_text": "Mantle Cell"}, {"start": 94, "end": 98, "probability": 0.5004, "type": "Other", "normalized_text": "RCHOP"}, {"start": 100, "end": 103, "probability": 0.5465, "type": "Other", "normalized_text": "DHAP"}, {"start": 107, "end": 115, "probability": 0.5074, "type": "Other", "normalized_text": "ibrutinib"}, {"start": 129, "end": 133, "probability": 0.505, "type": "Other", "normalized_text": "RCHOP"}, {"start": 135, "end": 138, "probability": 0.4628, "type": "Other", "normalized_text": "DHAP"}, {"start": 165, "end": 169, "probability": 0.481, "type": "Other", "normalized_text": "RCHOP"}, {"start": 171, "end": 174, "probability": 0.508, "type": "Other", "normalized_text": "DHAP"}, {"start": 275, "end": 283, "probability": 0.5558, "type": "Other", "normalized_text": "ibrutinib"}], "urls": [{"start": 290, "end": 313, "url": "https://t.co/btoPwYi8KK", "expanded_url": "https://twitter.com/AaronGoodman33/status/1599925397139099648/photo/1", "display_url": "pic.twitter.com/btoPwYi8KK", "media_key": "3_1599925066690502656"}, {"start": 314, "end": 337, "url": "https://t.co/pG7exZwa7f", "expanded_url": "https://twitter.com/AaronGoodman33/status/1599093726345056256", "display_url": "twitter.com/AaronGoodman33\u2026"}], "hashtags": [{"start": 0, "end": 6, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1599925397139099648"], "source": "Twitter Web App", "created_at": "2022-12-06T00:35:14.000Z"}, {"text": "My smoldering myeloma treatment guidelines!", "conversation_id": "1599904633711136769", "lang": "en", "author_id": "854692626015993857", "id": "1599904633711136769", "entities": {"annotations": [{"start": 14, "end": 20, "probability": 0.7568, "type": "Other", "normalized_text": "myeloma"}]}, "edit_history_tweet_ids": ["1599904633711136769"], "source": "Twitter for iPhone", "created_at": "2022-12-05T23:12:44.000Z"}, {"text": "@VPrasadMDMPH Are you the discuss any at #ASH22 this year?  Would be interesting and educational.", "conversation_id": "1599859955275735040", "lang": "en", "author_id": "854692626015993857", "id": "1599880052531154944", "referenced_tweets": [{"type": "replied_to", "id": "1599872039862824960"}], "entities": {"mentions": [{"start": 0, "end": 13, "username": "VPrasadMDMPH", "id": "1194962714"}], "annotations": [{"start": 42, "end": 46, "probability": 0.6748, "type": "Other", "normalized_text": "ASH22"}], "hashtags": [{"start": 41, "end": 47, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1599880052531154944"], "in_reply_to_user_id": "1194962714", "source": "Twitter for iPhone", "created_at": "2022-12-05T21:35:03.000Z"}, {"text": "@VPrasadMDMPH awesome, maybe you will be invited to the IMWG next?  I hope so.  I think in person people will realize we are all on the same team (how to best help our patients) we just have different approaches, we can all learn from each other", "conversation_id": "1599859955275735040", "lang": "en", "author_id": "854692626015993857", "id": "1599868146663690240", "referenced_tweets": [{"type": "replied_to", "id": "1599859955275735040"}], "entities": {"mentions": [{"start": 0, "end": 13, "username": "VPrasadMDMPH", "id": "1194962714"}], "annotations": [{"start": 56, "end": 59, "probability": 0.783, "type": "Other", "normalized_text": "IMWG"}]}, "edit_history_tweet_ids": ["1599868146663690240"], "in_reply_to_user_id": "1194962714", "source": "Twitter Web App", "created_at": "2022-12-05T20:47:44.000Z"}, {"text": "@ManniMD1 @Optum Yea DM is just so they look like they care for all of a second", "conversation_id": "1599826784786477057", "lang": "en", "author_id": "854692626015993857", "id": "1599829917805711360", "referenced_tweets": [{"type": "replied_to", "id": "1599826784786477057"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 10, "end": 16, "username": "Optum", "id": "318007077"}]}, "edit_history_tweet_ids": ["1599829917805711360"], "in_reply_to_user_id": "1269642863924609025", "source": "Twitter for iPhone", "created_at": "2022-12-05T18:15:50.000Z"}, {"text": "RT @Jmarksloan: Looking for an A+  hematology clinician investigator job in Boston?  We would love to hear from you. Graduating fellows wel\u2026", "conversation_id": "1599788024380162048", "lang": "en", "author_id": "854692626015993857", "id": "1599788024380162048", "referenced_tweets": [{"type": "retweeted", "id": "1599787532568252422"}], "entities": {"mentions": [{"start": 3, "end": 14, "username": "Jmarksloan", "id": "1578929666"}], "annotations": [{"start": 76, "end": 81, "probability": 0.9717, "type": "Place", "normalized_text": "Boston"}]}, "edit_history_tweet_ids": ["1599788024380162048"], "source": "Twitter Web App", "created_at": "2022-12-05T15:29:22.000Z"}, {"text": "@DeleeuwHalley So far so good", "conversation_id": "1599557478538043394", "lang": "en", "author_id": "854692626015993857", "id": "1599580615590154241", "referenced_tweets": [{"type": "replied_to", "id": "1599578871611158530"}], "entities": {"mentions": [{"start": 0, "end": 14, "username": "DeleeuwHalley", "id": "1126106500701806592"}]}, "edit_history_tweet_ids": ["1599580615590154241"], "in_reply_to_user_id": "1126106500701806592", "source": "Twitter for iPhone", "created_at": "2022-12-05T01:45:12.000Z"}, {"text": "@VPrasadMDMPH Yes this is my first book recommendation from you other than to read \u201cMalignant\u201d but that doesn\u2019t count.", "conversation_id": "1599557478538043394", "lang": "en", "author_id": "854692626015993857", "id": "1599561683084922880", "referenced_tweets": [{"type": "replied_to", "id": "1599560167322181632"}], "entities": {"mentions": [{"start": 0, "end": 13, "username": "VPrasadMDMPH", "id": "1194962714"}], "annotations": [{"start": 84, "end": 92, "probability": 0.9374, "type": "Other", "normalized_text": "Malignant"}]}, "edit_history_tweet_ids": ["1599561683084922880"], "in_reply_to_user_id": "1194962714", "source": "Twitter for iPhone", "created_at": "2022-12-05T00:29:58.000Z"}, {"text": "Excited to read this! https://t.co/4jYeJbKTAe", "conversation_id": "1599557478538043394", "lang": "en", "author_id": "854692626015993857", "id": "1599557478538043394", "edit_history_tweet_ids": ["1599557478538043394"], "entities": {"urls": [{"start": 22, "end": 45, "url": "https://t.co/4jYeJbKTAe", "expanded_url": "https://twitter.com/AaronGoodman33/status/1599557478538043394/photo/1", "display_url": "pic.twitter.com/4jYeJbKTAe", "media_key": "3_1599557463140802560"}]}, "source": "Twitter for iPhone", "created_at": "2022-12-05T00:13:15.000Z"}, {"text": "RT @ManniMD1: Is it fair for us to politely ask (without disrespecting the people being interviewed) who pays @TargetedOnc for this content\u2026", "conversation_id": "1599445953060417537", "lang": "en", "author_id": "854692626015993857", "id": "1599445953060417537", "referenced_tweets": [{"type": "retweeted", "id": "1599445097224892418"}], "entities": {"mentions": [{"start": 3, "end": 12, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 110, "end": 122, "username": "TargetedOnc", "id": "726304448"}]}, "edit_history_tweet_ids": ["1599445953060417537"], "source": "Twitter for iPhone", "created_at": "2022-12-04T16:50:06.000Z"}, {"text": "@Dr_AmerZeidan if you read his tweets he does not agree with the statement, this was just a question", "conversation_id": "1599440890803630081", "lang": "en", "author_id": "854692626015993857", "id": "1599443737704206336", "referenced_tweets": [{"type": "replied_to", "id": "1599440890803630081"}], "entities": {"mentions": [{"start": 0, "end": 14, "username": "Dr_AmerZeidan", "id": "1144997352148787201"}]}, "edit_history_tweet_ids": ["1599443737704206336"], "in_reply_to_user_id": "1144997352148787201", "source": "Twitter Web App", "created_at": "2022-12-04T16:41:17.000Z"}, {"text": "@CoachBon @ManniMD1 No one would unless they are poorly consented for this trial.   The trial should be closed or at the very least amended to exclude intermediate risk.", "conversation_id": "1599057168103538690", "lang": "en", "author_id": "854692626015993857", "id": "1599425936197586944", "referenced_tweets": [{"type": "replied_to", "id": "1599416272323690496"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "CoachBon", "id": "913851074"}, {"start": 10, "end": 19, "username": "ManniMD1", "id": "1269642863924609025"}]}, "edit_history_tweet_ids": ["1599425936197586944"], "in_reply_to_user_id": "913851074", "source": "Twitter for iPhone", "created_at": "2022-12-04T15:30:33.000Z"}, {"text": "RT @Anand_88_Patel: The U Chicago Leukemia/myeloid program Twitter account is up and running! Give it a follow at @UChicagoLeuk\n\n@myeloidma\u2026", "conversation_id": "1599220929099628544", "lang": "en", "author_id": "854692626015993857", "id": "1599220929099628544", "referenced_tweets": [{"type": "retweeted", "id": "1599219692559745024"}], "entities": {"mentions": [{"start": 3, "end": 18, "username": "Anand_88_Patel", "id": "2417458314"}, {"start": 114, "end": 127, "username": "UChicagoLeuk", "id": "1599205265928224768"}], "annotations": [{"start": 26, "end": 41, "probability": 0.3423, "type": "Other", "normalized_text": "Chicago Leukemia"}, {"start": 43, "end": 49, "probability": 0.5948, "type": "Other", "normalized_text": "myeloid"}, {"start": 59, "end": 65, "probability": 0.9054, "type": "Other", "normalized_text": "Twitter"}]}, "edit_history_tweet_ids": ["1599220929099628544"], "source": "Twitter for iPhone", "created_at": "2022-12-04T01:55:56.000Z"}, {"text": "I didn\u2019t even think 20,000 people knew what smoldering myeloma even is. https://t.co/XErs9CqUKs", "conversation_id": "1599211552401674240", "lang": "en", "author_id": "854692626015993857", "id": "1599211552401674240", "referenced_tweets": [{"type": "quoted", "id": "1599210886518173697"}], "entities": {"annotations": [{"start": 55, "end": 61, "probability": 0.6104, "type": "Other", "normalized_text": "myeloma"}], "urls": [{"start": 72, "end": 95, "url": "https://t.co/XErs9CqUKs", "expanded_url": "https://twitter.com/VPrasadMDMPH/status/1599210886518173697", "display_url": "twitter.com/VPrasadMDMPH/s\u2026"}]}, "edit_history_tweet_ids": ["1599211552401674240"], "source": "Twitter for iPhone", "created_at": "2022-12-04T01:18:40.000Z"}, {"text": "@geekbabe @BrownHospMed All natural", "conversation_id": "1599142217792516096", "lang": "en", "author_id": "854692626015993857", "id": "1599207737229185029", "referenced_tweets": [{"type": "replied_to", "id": "1599207509738209280"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "geekbabe", "id": "18792477"}, {"start": 10, "end": 23, "username": "BrownHospMed", "id": "1493597471074832393"}]}, "edit_history_tweet_ids": ["1599207737229185029"], "in_reply_to_user_id": "18792477", "source": "Twitter for iPhone", "created_at": "2022-12-04T01:03:31.000Z"}, {"text": "An interesting commentary I just read by \u2066@RahulBanerjeeMD\u2069 and \u2066@VPrasadMDMPH\u2069!\n\nAre Observational, Real-World Studies Suitable to Make Cancer Treatment Recommendations? | Oncology | JAMA Network Open | JAMA Network https://t.co/ls6afOA0Yx", "conversation_id": "1599201271558287360", "lang": "en", "author_id": "854692626015993857", "id": "1599201271558287360", "entities": {"mentions": [{"start": 42, "end": 58, "username": "RahulBanerjeeMD", "id": "26399236"}, {"start": 65, "end": 78, "username": "VPrasadMDMPH", "id": "1194962714"}], "annotations": [{"start": 165, "end": 172, "probability": 0.45, "type": "Other", "normalized_text": "ions? | "}, {"start": 176, "end": 192, "probability": 0.5921, "type": "Other", "normalized_text": "ology | JAMA Netw"}, {"start": 196, "end": 207, "probability": 0.6099, "type": "Other", "normalized_text": " Open | JAMA"}], "urls": [{"start": 217, "end": 240, "url": "https://t.co/ls6afOA0Yx", "expanded_url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2768843", "display_url": "jamanetwork.com/journals/jaman\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1599223661332140032/7VAoLwZX?format=jpg&name=orig", "width": 1600, "height": 840}, {"url": "https://pbs.twimg.com/news_img/1599223661332140032/7VAoLwZX?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Are Observational, Real-World Studies Suitable to Make Cancer Treatment Recommendations?", "description": "Kumar et al1 added a new chapter to a decades-long debate about whether observational studies\u2014nonrandomized comparative effectiveness research (CER)\u2014can replace randomized clinical trials (RCTs) to assess the efficacy of therapies. Their work is timely. The 21st Century Cures Act has empowered the...", "unwound_url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2768843"}]}, "edit_history_tweet_ids": ["1599201271558287360"], "source": "Twitter for iPhone", "created_at": "2022-12-04T00:37:49.000Z"}, {"text": "@LeonidasPlatan1 @BrownHospMed A teaching point.  Per WHO 2022 \"hairy cell leukemia variant\" no longer exists.  \n\nIt is now known as \"splenic B-cell lymphoma/leukemia with prominent nucleoli\"!\n\n@sanamloghavi https://t.co/gala98hYjA", "conversation_id": "1599142217792516096", "lang": "en", "author_id": "854692626015993857", "id": "1599194264122306560", "referenced_tweets": [{"type": "replied_to", "id": "1599193443711930369"}], "entities": {"mentions": [{"start": 0, "end": 16, "username": "LeonidasPlatan1", "id": "1117857169528033280"}, {"start": 17, "end": 30, "username": "BrownHospMed", "id": "1493597471074832393"}, {"start": 194, "end": 207, "username": "sanamloghavi", "id": "3076847052"}], "annotations": [{"start": 54, "end": 56, "probability": 0.4059, "type": "Other", "normalized_text": "WHO"}, {"start": 75, "end": 90, "probability": 0.484, "type": "Other", "normalized_text": "leukemia variant"}, {"start": 134, "end": 140, "probability": 0.5508, "type": "Other", "normalized_text": "splenic"}, {"start": 144, "end": 147, "probability": 0.4682, "type": "Other", "normalized_text": "cell"}, {"start": 158, "end": 165, "probability": 0.6418, "type": "Other", "normalized_text": "leukemia"}], "urls": [{"start": 208, "end": 231, "url": "https://t.co/gala98hYjA", "expanded_url": "https://twitter.com/AaronGoodman33/status/1599194264122306560/photo/1", "display_url": "pic.twitter.com/gala98hYjA", "media_key": "3_1599194254340808705"}]}, "edit_history_tweet_ids": ["1599194264122306560"], "in_reply_to_user_id": "1117857169528033280", "source": "Twitter Web App", "created_at": "2022-12-04T00:09:58.000Z"}, {"text": "@BrownHospMed https://t.co/8MYLg8olPs", "conversation_id": "1599142217792516096", "lang": "qme", "author_id": "854692626015993857", "id": "1599192787391778820", "referenced_tweets": [{"type": "replied_to", "id": "1599142217792516096"}], "entities": {"mentions": [{"start": 0, "end": 13, "username": "BrownHospMed", "id": "1493597471074832393"}], "urls": [{"start": 14, "end": 37, "url": "https://t.co/8MYLg8olPs", "expanded_url": "https://twitter.com/AaronGoodman33/status/1599192787391778820/photo/1", "display_url": "pic.twitter.com/8MYLg8olPs", "media_key": "3_1599192781229989888"}]}, "edit_history_tweet_ids": ["1599192787391778820"], "in_reply_to_user_id": "1493597471074832393", "source": "Twitter for iPhone", "created_at": "2022-12-04T00:04:06.000Z"}, {"text": "RT @Plenary_Session: Now on the audio feed @Plenary_Session!", "conversation_id": "1599187885626126336", "lang": "en", "author_id": "854692626015993857", "id": "1599187885626126336", "referenced_tweets": [{"type": "retweeted", "id": "1599137975329492992"}], "entities": {"mentions": [{"start": 3, "end": 19, "username": "Plenary_Session", "id": "1028063001755103233"}, {"start": 43, "end": 59, "username": "Plenary_Session", "id": "1028063001755103233"}]}, "edit_history_tweet_ids": ["1599187885626126336"], "source": "Twitter for iPhone", "created_at": "2022-12-03T23:44:38.000Z"}, {"text": "RT @massimodigioia: Why I love Twitter\u2026", "conversation_id": "1599187868223967232", "lang": "en", "author_id": "854692626015993857", "id": "1599187868223967232", "referenced_tweets": [{"type": "retweeted", "id": "1599145203348082689"}], "entities": {"mentions": [{"start": 3, "end": 18, "username": "massimodigioia", "id": "461579451"}], "annotations": [{"start": 31, "end": 37, "probability": 0.9761, "type": "Other", "normalized_text": "Twitter"}]}, "edit_history_tweet_ids": ["1599187868223967232"], "source": "Twitter for iPhone", "created_at": "2022-12-03T23:44:33.000Z"}, {"text": "RT @Timothee_MD: Wow! Great new video series from Vinay !\nI enjoyed it a lot !\n\nMed Twitter is alive, for sure !\nWell done \ud83d\udc4f", "conversation_id": "1599175260347469824", "lang": "en", "author_id": "854692626015993857", "id": "1599175260347469824", "referenced_tweets": [{"type": "retweeted", "id": "1599169972072169472"}], "entities": {"mentions": [{"start": 3, "end": 15, "username": "Timothee_MD", "id": "1472332068914962433"}], "annotations": [{"start": 50, "end": 54, "probability": 0.7104, "type": "Other", "normalized_text": "Vinay"}, {"start": 84, "end": 90, "probability": 0.9896, "type": "Other", "normalized_text": "Twitter"}]}, "edit_history_tweet_ids": ["1599175260347469824"], "source": "Twitter for iPhone", "created_at": "2022-12-03T22:54:27.000Z"}, {"text": "Come work @UCSDHealth @ucsdcancer and live in America\u2019s finest city while working with amazing colleagues. https://t.co/ICdbVyNjej", "conversation_id": "1599151777923768320", "lang": "en", "author_id": "854692626015993857", "id": "1599151777923768320", "referenced_tweets": [{"type": "quoted", "id": "1599082579202027521"}], "entities": {"mentions": [{"start": 10, "end": 21, "username": "UCSDHealth", "id": "107258201"}, {"start": 22, "end": 33, "username": "UCSDCancer", "id": "1473383250995281922"}], "annotations": [{"start": 46, "end": 52, "probability": 0.9431, "type": "Place", "normalized_text": "America"}], "urls": [{"start": 107, "end": 130, "url": "https://t.co/ICdbVyNjej", "expanded_url": "https://twitter.com/Dr_RShatsky/status/1599082579202027521", "display_url": "twitter.com/Dr_RShatsky/st\u2026"}]}, "edit_history_tweet_ids": ["1599151777923768320"], "source": "Twitter for iPhone", "created_at": "2022-12-03T21:21:09.000Z"}, {"text": "RT @Plenary_Session: Plenary Session Downloads are Insane\nMillions of downloads &amp; growing\nMost Popular Heme Onc Podcast Globally\nThanks to\u2026", "conversation_id": "1599150142997024768", "lang": "en", "author_id": "854692626015993857", "id": "1599150142997024768", "referenced_tweets": [{"type": "retweeted", "id": "1599138243228073985"}], "entities": {"mentions": [{"start": 3, "end": 19, "username": "Plenary_Session", "id": "1028063001755103233"}]}, "edit_history_tweet_ids": ["1599150142997024768"], "source": "Twitter for iPhone", "created_at": "2022-12-03T21:14:39.000Z"}, {"text": "@VPrasadMDMPH @Plenary_Session It was more of a friendly debate than a battle.  It was some good old fashioned precovid  #medtwitter.", "conversation_id": "1599126088411541504", "lang": "en", "author_id": "854692626015993857", "id": "1599127168306491392", "referenced_tweets": [{"type": "replied_to", "id": "1599126088411541504"}], "entities": {"mentions": [{"start": 0, "end": 13, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 14, "end": 30, "username": "Plenary_Session", "id": "1028063001755103233"}], "annotations": [{"start": 122, "end": 131, "probability": 0.6611, "type": "Other", "normalized_text": "medtwitter"}], "hashtags": [{"start": 121, "end": 132, "tag": "medtwitter"}]}, "edit_history_tweet_ids": ["1599127168306491392"], "in_reply_to_user_id": "1194962714", "source": "Twitter for iPhone", "created_at": "2022-12-03T19:43:21.000Z"}, {"text": "This should be interesting. https://t.co/qCmaJIpKGR", "conversation_id": "1599126916430430208", "lang": "en", "author_id": "854692626015993857", "id": "1599126916430430208", "referenced_tweets": [{"type": "quoted", "id": "1599126088411541504"}], "edit_history_tweet_ids": ["1599126916430430208"], "entities": {"urls": [{"start": 28, "end": 51, "url": "https://t.co/qCmaJIpKGR", "expanded_url": "https://twitter.com/vprasadmdmph/status/1599126088411541504", "display_url": "twitter.com/vprasadmdmph/s\u2026"}]}, "source": "Twitter for iPhone", "created_at": "2022-12-03T19:42:21.000Z"}, {"text": "@GKaurMD Thank you for your feedback.   Please see tweets describing wonderful practice changing trials at ASH.  Unfortunately none were myeloma trials this year. There is always next year.", "conversation_id": "1599115678836924416", "lang": "en", "author_id": "854692626015993857", "id": "1599123604607668224", "referenced_tweets": [{"type": "replied_to", "id": "1599115678836924416"}], "entities": {"mentions": [{"start": 0, "end": 8, "username": "GKaurMD", "id": "28731834"}], "annotations": [{"start": 107, "end": 109, "probability": 0.539, "type": "Organization", "normalized_text": "ASH"}]}, "edit_history_tweet_ids": ["1599123604607668224"], "in_reply_to_user_id": "28731834", "source": "Twitter for iPhone", "created_at": "2022-12-03T19:29:12.000Z"}, {"text": "@GuiperiniMD @chadinabhan Maybe I\u2019ll bring my guitar.  @ASkarbnik will you have access to keyboard?", "conversation_id": "1598826846082121728", "lang": "en", "author_id": "854692626015993857", "id": "1599121358063304704", "referenced_tweets": [{"type": "replied_to", "id": "1599110786210676736"}], "entities": {"mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 13, "end": 25, "username": "chadinabhan", "id": "2212735524"}, {"start": 55, "end": 65, "username": "ASkarbnik", "id": "999010996034338818"}]}, "edit_history_tweet_ids": ["1599121358063304704"], "in_reply_to_user_id": "1294745239656202240", "source": "Twitter for iPhone", "created_at": "2022-12-03T19:20:16.000Z"}, {"text": "Classic Podcast with \u2066@chadinabhan\u2069 where I debate the CMO of Karyopharm on the role of selinexor and the infamous BOSTON study. https://t.co/dYRC5XHjkk", "conversation_id": "1599120209306013697", "lang": "en", "author_id": "854692626015993857", "id": "1599120209306013697", "entities": {"mentions": [{"start": 22, "end": 34, "username": "chadinabhan", "id": "2212735524"}], "annotations": [{"start": 58, "end": 67, "probability": 0.7215, "type": "Other", "normalized_text": " of Karyop"}, {"start": 84, "end": 92, "probability": 0.6141, "type": "Other", "normalized_text": " of selin"}], "urls": [{"start": 129, "end": 152, "url": "https://t.co/dYRC5XHjkk", "expanded_url": "https://podcasts.apple.com/us/podcast/healthcare-unfiltered/id1534737585?i=1000504388176", "display_url": "podcasts.apple.com/us/podcast/hea\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1599120211851952129/g84ya1ma?format=jpg&name=orig", "width": 1200, "height": 600}, {"url": "https://pbs.twimg.com/news_img/1599120211851952129/g84ya1ma?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "\u200eHealthcare Unfiltered: Drug Approvals and Real-World Use: The Case of Selinexor in Multiple Myeloma on Apple Podcasts", "description": "\u200eShow Healthcare Unfiltered, Ep Drug Approvals and Real-World Use: The Case of Selinexor in Multiple Myeloma - Jan 5, 2021", "unwound_url": "https://podcasts.apple.com/us/podcast/healthcare-unfiltered/id1534737585?i=1000504388176"}]}, "edit_history_tweet_ids": ["1599120209306013697"], "source": "Twitter for iPhone", "created_at": "2022-12-03T19:15:42.000Z"}, {"text": "RT @Sthanu5: @AaronGoodman33 Chronic Granulomatous Disease\n\ndefective function of the nicotinamide adenine dinucleotide phosphate (NADPH) o\u2026", "conversation_id": "1599119141205868544", "lang": "en", "author_id": "854692626015993857", "id": "1599119141205868544", "referenced_tweets": [{"type": "retweeted", "id": "1599106602958999552"}], "entities": {"mentions": [{"start": 3, "end": 11, "username": "Sthanu5", "id": "821765042051784705"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 29, "end": 57, "probability": 0.8481, "type": "Other", "normalized_text": "Chronic Granulomatous Disease"}, {"start": 131, "end": 135, "probability": 0.5084, "type": "Other", "normalized_text": "NADPH"}]}, "edit_history_tweet_ids": ["1599119141205868544"], "source": "Twitter for iPhone", "created_at": "2022-12-03T19:11:28.000Z"}, {"text": "@sanamloghavi @MRLitzow @SelinaLugerMD @MartinTallman @eaonc @CMullighan Congrats Dr @MRLitzow   I did not realize you were on Twitter.  Practice changing for our patients!", "conversation_id": "1599115085322285056", "lang": "en", "author_id": "854692626015993857", "id": "1599116192475910144", "referenced_tweets": [{"type": "replied_to", "id": "1599115085322285056"}], "entities": {"mentions": [{"start": 0, "end": 13, "username": "sanamloghavi", "id": "3076847052"}, {"start": 14, "end": 23, "username": "MRLitzow", "id": "973216285"}, {"start": 24, "end": 38, "username": "SelinaLugerMD", "id": "4827569945"}, {"start": 39, "end": 53, "username": "MartinTallman", "id": "1334487799718961153"}, {"start": 54, "end": 60, "username": "eaonc", "id": "2201478360"}, {"start": 61, "end": 72, "username": "CMullighan", "id": "1579638991"}, {"start": 85, "end": 94, "username": "MRLitzow", "id": "973216285"}], "annotations": [{"start": 127, "end": 133, "probability": 0.705, "type": "Other", "normalized_text": "Twitter"}]}, "edit_history_tweet_ids": ["1599116192475910144"], "in_reply_to_user_id": "3076847052", "source": "Twitter for iPhone", "created_at": "2022-12-03T18:59:45.000Z"}], "includes": {"users": [{"id": "854692626015993857", "name": "Aaron Goodman - \u201cPapa Heme\u201d", "username": "AaronGoodman33"}, {"id": "20281991", "name": "David Sparksman \ud83c\udde9\ud83c\uddf0\ud83c\uddea\ud83c\uddfa", "username": "DSparky1"}, {"id": "824315782947631104", "name": "Shematologist, MD", "username": "acweyand"}, {"id": "898851661", "name": "Chris Strouse", "username": "strouse_chris"}, {"id": "75550503", "name": "\ud835\udde1\ud835\uddf6\ud835\uddf5\ud835\uddee\ud835\uddff \ud835\uddd7\ud835\uddf2\ud835\ude00\ud835\uddee\ud835\uddf6", "username": "nihardesai7"}, {"id": "1269642863924609025", "name": "Manni Mohyuddin", "username": "ManniMD1"}, {"id": "918471705408016384", "name": "Pallawi Torka", "username": "PallawiTorkaMD"}, {"id": "215681001", "name": "HemeDocRuns, MD", "username": "allisonp1979"}, {"id": "1334487799718961153", "name": "Martin S. Tallman, MD", "username": "MartinTallman"}, {"id": "1194962714", "name": "Vinay Prasad MD MPH", "username": "VPrasadMDMPH"}, {"id": "2212735524", "name": "chadi nabhan MD, MBA, FACP", "username": "chadinabhan"}, {"id": "149477915", "name": "Arjun D. Law", "username": "Haemophage"}, {"id": "719175246050410496", "name": "Andrew M. Evens, DO, MBA, MSc", "username": "DrAEvens"}, {"id": "53395744", "name": "Shernan Holtan MD", "username": "sghmd"}, {"id": "3497730012", "name": "barttels", "username": "barttels2"}, {"id": "1144997352148787201", "name": "Amer Zeidan MBBS,MHS \u200f\u0639\u0627\u0645\u0631 \u0632\u064a\u062f\u0627\u0646", "username": "Dr_AmerZeidan"}, {"id": "626650397", "name": "Michael Slade, MD", "username": "MichaelJSlade"}, {"id": "537795028", "name": "Jonathan Reiner", "username": "JReinerMD"}, {"id": "782764410", "name": "Justin Kaner", "username": "JKanerMD"}, {"id": "18821994", "name": "David Russler-Germain, MD/PhD", "username": "dgermain21"}, {"id": "1026947037080772610", "name": "Al-Ola A Abdallah MD", "username": "Abdallah81MD"}, {"id": "3154223927", "name": "Elli Papaemmanuil, PhD", "username": "PapaemmanuilLab"}, {"id": "999010996034338818", "name": "Alan Skarbnik", "username": "ASkarbnik"}, {"id": "354168091", "name": "Matthew Mei", "username": "matthew_mei"}, {"id": "2170420038", "name": "David Young M.D.", "username": "davideyoungmd"}, {"id": "1126106500701806592", "name": "Halley Deleeuw", "username": "DeleeuwHalley"}, {"id": "913851074", "name": "Coach Bonnie", "username": "CoachBon"}, {"id": "18792477", "name": "Jean Parks", "username": "geekbabe"}, {"id": "1117857169528033280", "name": "Leonidas Platanias, MD", "username": "LeonidasPlatan1"}, {"id": "1493597471074832393", "name": "Brown Hospital Medicine", "username": "BrownHospMed"}, {"id": "28731834", "name": "Gurbakhash Kaur", "username": "GKaurMD"}, {"id": "1294745239656202240", "name": "Guilherme Perini, MD", "username": "GuiperiniMD"}, {"id": "3076847052", "name": "Sanam Loghavi, MD \u0635\u0646\u0645 \u0644\u063a\u0648\u06cc \ud83d\udd2c\ud83e\uddec", "username": "sanamloghavi"}], "tweets": [{"text": "Great to spend time with @VincentRK @AaronGoodman33 @JatinShahMD and Dr. Park (not of twitter; we are trying) speaking with fellows about career paths and opportunities. Right here @ASH_hematology #ASH22 \n\nAnother program #ASCO23 ASCO being planned. https://t.co/34m8cJmQeI", "conversation_id": "1601409465948872704", "lang": "en", "author_id": "2212735524", "id": "1601409465948872704", "entities": {"mentions": [{"start": 25, "end": 35, "username": "VincentRK", "id": "24261916"}, {"start": 36, "end": 51, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 52, "end": 64, "username": "JatinShahMD", "id": "221642631"}, {"start": 181, "end": 196, "username": "ASH_hematology", "id": "84072624"}], "urls": [{"start": 250, "end": 273, "url": "https://t.co/34m8cJmQeI", "expanded_url": "https://twitter.com/chadinabhan/status/1601409465948872704/photo/1", "display_url": "pic.twitter.com/34m8cJmQeI", "media_key": "3_1601409377763790850"}], "hashtags": [{"start": 197, "end": 203, "tag": "ASH22"}, {"start": 222, "end": 229, "tag": "ASCO23"}]}, "edit_history_tweet_ids": ["1601409465948872704"], "source": "Twitter for iPhone", "created_at": "2022-12-10T02:52:24.000Z"}, {"text": "Right here at @ASH_hematology #ASH22 with @AaronGoodman33 &amp; @VincentRK discussing science, mentorship, and music. \n\nGreat fellowship mentorship program today. https://t.co/meTuqRdRda", "conversation_id": "1601400573555019776", "lang": "en", "author_id": "2212735524", "id": "1601400573555019776", "entities": {"mentions": [{"start": 14, "end": 29, "username": "ASH_hematology", "id": "84072624"}, {"start": 42, "end": 57, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 64, "end": 74, "username": "VincentRK", "id": "24261916"}], "urls": [{"start": 163, "end": 186, "url": "https://t.co/meTuqRdRda", "expanded_url": "https://twitter.com/chadinabhan/status/1601400573555019776/photo/1", "display_url": "pic.twitter.com/meTuqRdRda", "media_key": "3_1601400455678001152"}], "hashtags": [{"start": 30, "end": 36, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1601400573555019776"], "source": "Twitter for iPhone", "created_at": "2022-12-10T02:17:03.000Z"}, {"text": "@AaronGoodman33 @acweyand God job you went for that run", "conversation_id": "1601285083566161922", "lang": "en", "author_id": "20281991", "id": "1601317972932726784", "referenced_tweets": [{"type": "replied_to", "id": "1601285083566161922"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 25, "username": "acweyand", "id": "824315782947631104"}]}, "edit_history_tweet_ids": ["1601317972932726784"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter Web App", "created_at": "2022-12-09T20:48:50.000Z"}, {"text": "Hey @AaronGoodman33 how\u2019s that Nola humidity treating those curls? #ASH22 https://t.co/jppRbbS06h", "conversation_id": "1601350353915875330", "lang": "en", "author_id": "824315782947631104", "id": "1601350353915875330", "entities": {"mentions": [{"start": 4, "end": 19, "username": "AaronGoodman33", "id": "854692626015993857"}], "urls": [{"start": 74, "end": 97, "url": "https://t.co/jppRbbS06h", "expanded_url": "https://twitter.com/acweyand/status/1601350353915875330/photo/1", "display_url": "pic.twitter.com/jppRbbS06h", "media_key": "3_1601350350509940737"}], "hashtags": [{"start": 67, "end": 73, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1601350353915875330"], "source": "Twitter for iPhone", "created_at": "2022-12-09T22:57:30.000Z"}, {"text": "@AaronGoodman33 I may be biased but this is the best article: https://t.co/zQG7VqJcp4", "conversation_id": "1601300744644472832", "lang": "en", "author_id": "16827782", "id": "1601328957978456064", "referenced_tweets": [{"type": "replied_to", "id": "1601300744644472832"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}], "urls": [{"start": 62, "end": 85, "url": "https://t.co/zQG7VqJcp4", "expanded_url": "https://ashpublications.org/hematology/article/2022/1/467/493547/Anticoagulant-therapy-for-women-implications-for", "display_url": "ashpublications.org/hematology/art\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1601328965863747585/V81JEyYk?format=png&name=orig", "width": 520, "height": 675}, {"url": "https://pbs.twimg.com/news_img/1601328965863747585/V81JEyYk?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Anticoagulant therapy for women: implications for menstruation, pregnancy, and lactation", "description": "Abstract. Estrogen exposure, in the setting of pregnancy, the postpartum state, combined hormonal contraceptives (CHCs), or hormone therapy use, has been clearl", "unwound_url": "https://ashpublications.org/hematology/article/2022/1/467/493547/Anticoagulant-therapy-for-women-implications-for"}]}, "edit_history_tweet_ids": ["1601328957978456064"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for iPhone", "created_at": "2022-12-09T21:32:29.000Z"}, {"text": "Yes the ASH Education Book has been released!!!\n\nChristmas (Hannukah) is a little early this year!\n\nhttps://t.co/HB3ggnspZN\n\n#ASH22 https://t.co/b1V2yZphMh", "conversation_id": "1601300744644472832", "lang": "en", "author_id": "854692626015993857", "id": "1601300744644472832", "entities": {"annotations": [{"start": 8, "end": 20, "probability": 0.6312, "type": "Other", "normalized_text": "ASH Education"}, {"start": 60, "end": 67, "probability": 0.4838, "type": "Person", "normalized_text": "Hannukah"}], "urls": [{"start": 100, "end": 123, "url": "https://t.co/HB3ggnspZN", "expanded_url": "https://ashpublications.org/hematology", "display_url": "ashpublications.org/hematology", "images": [{"url": "https://pbs.twimg.com/news_img/1601300750361333760/cCTjZZww?format=png&name=orig", "width": 520, "height": 675}, {"url": "https://pbs.twimg.com/news_img/1601300750361333760/cCTjZZww?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Hematology | American Society of Hematology", "description": "The Hematology ASH Education Program 2022 provides review articles from the Education Program at the 2022 ASH Annual Meeting. In this publication, each chapter relates to a different session presented at the meeting, spanning the spectrum from basic discovery and disease pathogenesis to the clinical application at the bedside. This activity is supported by educational grants from AstraZeneca; GlaxoSmithKline; Incyte Corp.; Jazz Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; and Novartis Pharmaceuticals", "unwound_url": "https://ashpublications.org/hematology"}, {"start": 132, "end": 155, "url": "https://t.co/b1V2yZphMh", "expanded_url": "https://twitter.com/AaronGoodman33/status/1601300744644472832/photo/1", "display_url": "pic.twitter.com/b1V2yZphMh", "media_key": "3_1601300676432330754"}], "hashtags": [{"start": 125, "end": 131, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1601300744644472832"], "source": "Twitter Web App", "created_at": "2022-12-09T19:40:22.000Z"}, {"text": "@AaronGoodman33 @nihardesai7 Do you find the IMWG frailty score clinically useful for this? I haven\u2019t been able to convince myself to change course when it disagrees with my gestalt yet", "conversation_id": "1601335757213696003", "lang": "en", "author_id": "898851661", "id": "1601342476056670208", "referenced_tweets": [{"type": "replied_to", "id": "1601337861814759424"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 28, "username": "nihardesai7", "id": "75550503"}]}, "edit_history_tweet_ids": ["1601342476056670208"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for iPhone", "created_at": "2022-12-09T22:26:12.000Z"}, {"text": "@AaronGoodman33 How old is old ?", "conversation_id": "1601335757213696003", "lang": "en", "author_id": "75550503", "id": "1601336046696165377", "referenced_tweets": [{"type": "replied_to", "id": "1601335757213696003"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "edit_history_tweet_ids": ["1601336046696165377"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for Android", "created_at": "2022-12-09T22:00:39.000Z"}, {"text": "\u2b50\ufe0fPractice changing abstract\n\n\u2b50\ufe0fMel140 fails to beat len/dex in 60-75 year olds\n\nThis combined with lack of OS benefit to date in DETERMINATION/IFM 2009 has considerably lessened enthusiasm to transpl (esp mel140) standard risk #mmsm above age 70.\n\n#ASH22\nhttps://t.co/9NykX99A65", "conversation_id": "1601305074629648385", "lang": "en", "author_id": "1269642863924609025", "id": "1601305074629648385", "entities": {"annotations": [{"start": 130, "end": 142, "probability": 0.5258, "type": "Other", "normalized_text": "DETERMINATION"}, {"start": 144, "end": 146, "probability": 0.7035, "type": "Other", "normalized_text": "IFM"}], "urls": [{"start": 256, "end": 279, "url": "https://t.co/9NykX99A65", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159357.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed M", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP Hematology Disease Topics & Pathways: Research, clinical trials, adult, Clinical Research, Plasma Cell Disorders, Combination therapy, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Study Population, Human 1 Clinic of Hematology, Oncology and Stem Cell Transplantation, Muenchen Klinik Schwabing, Munich, Germany 2 Klinikum Nuernberg, Nuernberg,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159357.html"}], "hashtags": [{"start": 228, "end": 233, "tag": "mmsm"}, {"start": 249, "end": 255, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1601305074629648385"], "source": "Twitter for iPhone", "created_at": "2022-12-09T19:57:35.000Z"}, {"text": "Congratulations to our faculty, Dr. @AleckAmalia and Dr. Anne Shapiro representing @UCSDAnes- clinical decision support to reduce anesthetic greenhouse gasses across @UofCAHealth.\n\n@UCSDHealth @UCSDnews @UCSDfacaffairs @UCSDHealthSci \n@UCSDMedSchool https://t.co/Nrg0gqmJj0", "conversation_id": "1601063795941482497", "lang": "en", "author_id": "1542877210356330497", "id": "1601063795941482497", "referenced_tweets": [{"type": "quoted", "id": "1600887070377250819"}], "entities": {"mentions": [{"start": 36, "end": 48, "username": "AleckAmalia", "id": "1331336294828437504"}, {"start": 83, "end": 92, "username": "UCSDAnes", "id": "1542877210356330497"}, {"start": 166, "end": 178, "username": "UofCAHealth", "id": "1188993986465157120"}, {"start": 181, "end": 192, "username": "UCSDHealth", "id": "107258201"}, {"start": 193, "end": 202, "username": "UCSDnews", "id": "9233092"}, {"start": 203, "end": 218, "username": "UCSDfacaffairs", "id": "931577353351741440"}, {"start": 219, "end": 233, "username": "UCSDHealthSci", "id": "951918498560712704"}, {"start": 235, "end": 249, "username": "UCSDMedSchool", "id": "1488929426662322177"}], "annotations": [{"start": 57, "end": 68, "probability": 0.7686, "type": "Other", "normalized_text": "Anne Shapiro"}], "urls": [{"start": 250, "end": 273, "url": "https://t.co/Nrg0gqmJj0", "expanded_url": "https://twitter.com/jmirpub/status/1600887070377250819", "display_url": "twitter.com/jmirpub/status\u2026"}]}, "edit_history_tweet_ids": ["1601063795941482497"], "source": "Twitter for iPhone", "created_at": "2022-12-09T03:58:49.000Z"}, {"text": "Check out our (+ @sabobillo @CwynKate) review on #CNSprophylaxis in this year's educational book\nhttps://t.co/3eq1rMVIZ6\n\nTo be presented by @CwynKate in Controversies in Aggressive NHL educational session Sat 9.30 https://t.co/3EgmpAMJsa", "conversation_id": "1601307741355913217", "lang": "en", "author_id": "45443577", "id": "1601307741355913217", "referenced_tweets": [{"type": "quoted", "id": "1601300744644472832"}], "entities": {"mentions": [{"start": 17, "end": 27, "username": "sabobillo", "id": "829364688018407425"}, {"start": 28, "end": 37, "username": "CwynKate", "id": "879789995053240321"}, {"start": 141, "end": 150, "username": "CwynKate", "id": "879789995053240321"}], "urls": [{"start": 97, "end": 120, "url": "https://t.co/3eq1rMVIZ6", "expanded_url": "https://ashpublications.org/hematology/article/2022/1/138/493499/CNS-prophylaxis-in-aggressive-B-cell-lymphoma", "display_url": "ashpublications.org/hematology/art\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1601307750147174400/2ZARgRbw?format=png&name=orig", "width": 520, "height": 675}, {"url": "https://pbs.twimg.com/news_img/1601307750147174400/2ZARgRbw?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "CNS prophylaxis in aggressive B-cell lymphoma", "description": "Abstract. The prevention of central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) continues to be one of the most contentious areas of l", "unwound_url": "https://ashpublications.org/hematology/article/2022/1/138/493499/CNS-prophylaxis-in-aggressive-B-cell-lymphoma"}, {"start": 215, "end": 238, "url": "https://t.co/3EgmpAMJsa", "expanded_url": "https://twitter.com/AaronGoodman33/status/1601300744644472832", "display_url": "twitter.com/AaronGoodman33\u2026"}], "hashtags": [{"start": 49, "end": 64, "tag": "CNSprophylaxis"}]}, "edit_history_tweet_ids": ["1601307741355913217"], "source": "Twitter Web App", "created_at": "2022-12-09T20:08:11.000Z"}, {"text": "@AaronGoodman33 Cafe du Monde?", "conversation_id": "1601285083566161922", "lang": "fr", "author_id": "824315782947631104", "id": "1601301763319300096", "referenced_tweets": [{"type": "replied_to", "id": "1601301419155288065"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "edit_history_tweet_ids": ["1601301763319300096"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for iPhone", "created_at": "2022-12-09T19:44:25.000Z"}, {"text": "@AaronGoodman33 Ooh report back!", "conversation_id": "1601285083566161922", "lang": "en", "author_id": "824315782947631104", "id": "1601301238536028160", "referenced_tweets": [{"type": "replied_to", "id": "1601285083566161922"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "edit_history_tweet_ids": ["1601301238536028160"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for iPhone", "created_at": "2022-12-09T19:42:20.000Z"}, {"text": "Just spotted at #ASH22 \nThe brown doppelg\u00e4nger of @AaronGoodman33  \n\nOur fellow extraordinaire @RoswellPark @RoswellHemOnc and the moderator of @HemOncFellows @msalmanfaisal  \n\nYou guys need to give up your hair routine secrets. \ud83d\ude1c https://t.co/JAYtA6cG0l", "conversation_id": "1601259817154543616", "lang": "en", "author_id": "918471705408016384", "id": "1601259817154543616", "entities": {"mentions": [{"start": 50, "end": 65, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 95, "end": 107, "username": "RoswellPark", "id": "16044589"}, {"start": 108, "end": 122, "username": "RoswellHemOnc", "id": "1378011784674705409"}, {"start": 144, "end": 158, "username": "HemOncFellows", "id": "1357568654444003335"}, {"start": 159, "end": 173, "username": "msalmanfaisal", "id": "141154688"}], "annotations": [{"start": 17, "end": 21, "probability": 0.6422, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 231, "end": 254, "url": "https://t.co/JAYtA6cG0l", "expanded_url": "https://twitter.com/PallawiTorkaMD/status/1601259817154543616/photo/1", "display_url": "pic.twitter.com/JAYtA6cG0l", "media_key": "3_1601259811961819136"}], "hashtags": [{"start": 16, "end": 22, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1601259817154543616"], "source": "Twitter for iPhone", "created_at": "2022-12-09T16:57:45.000Z"}, {"text": "Let\u2019s look at 2 smoldering MM trials presented #ASH22 of from different(important) angles #mmsm \ud83e\uddf5\n\nASCENT trial (US)\nGEM-CESAR trial (Europe)\n\n\u27a1\ufe0fhttps://t.co/7fggQ0DrCd\n\u27a1\ufe0f https://t.co/rqgmPbMee8\n\nTreatment drugs and duration\ud83d\udc47\n\nASCENT:Dara-KRd(2yrs)\nGEM-CESAR:KRd+auto (~3yrs) https://t.co/ikAGsUMOJo", "conversation_id": "1601170628899323904", "lang": "en", "author_id": "774267564", "id": "1601170628899323904", "entities": {"annotations": [{"start": 113, "end": 114, "probability": 0.808, "type": "Place", "normalized_text": "US"}, {"start": 134, "end": 139, "probability": 0.8606, "type": "Place", "normalized_text": "Europe"}, {"start": 235, "end": 238, "probability": 0.381, "type": "Other", "normalized_text": "Dara"}], "urls": [{"start": 145, "end": 168, "url": "https://t.co/7fggQ0DrCd", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper168930.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Risk-adapted Treatment Strategies in Myeloma and Related Conditions Hematology Disease Topics & Pathways: Research, clinical trials, Biological therapies, Antibody Therapy, Clinical Research, Plasma Cell Disorders, Combination therapy, Diseases, Therapies, Lymphoid Malignancies, Human, Minimal Residual Disease Shaji K Kumar, MD 1, Melissa Alsina, MD** 2, Betsy Laplant, MS 3 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper168930.html"}, {"start": 172, "end": 195, "url": "https://t.co/rqgmPbMee8", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Plasma Cell Disorders, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Minimal Residual Disease Maria-Victoria Mateos, MD 1, Joaqu\u00edn Mart\u00ednez-L\u00f3pez, MD, PhD 2 *, Paula Rodr\u00edguez-Otero, MD, PhD 3 *, Jes\u00fas San-Miguel, MD, PhD 4, Veronica Gonzalez-Calle, MD, PhD 1 *,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper159606.html"}, {"start": 277, "end": 300, "url": "https://t.co/ikAGsUMOJo", "expanded_url": "https://twitter.com/HadidiSamer/status/1601170628899323904/photo/1", "display_url": "pic.twitter.com/ikAGsUMOJo", "media_key": "3_1601170620187918336"}], "hashtags": [{"start": 47, "end": 53, "tag": "ASH22"}, {"start": 90, "end": 95, "tag": "mmsm"}]}, "edit_history_tweet_ids": ["1601170628899323904"], "source": "Twitter for iPhone", "created_at": "2022-12-09T11:03:20.000Z"}, {"text": "So nice to top the impressions \ud83d\ude0a alongside the great @AaronGoodman33\nI will be releasing videos all through #ash22 #ash2022\nIt will be filmed on a phone selfie style.\ud83d\ude02 Hope that doesn't disappoint https://t.co/0CTFqUnaMk", "conversation_id": "1601119499625041923", "lang": "en", "author_id": "1194962714", "id": "1601119499625041923", "referenced_tweets": [{"type": "quoted", "id": "1601008586108174336"}], "entities": {"mentions": [{"start": 53, "end": 68, "username": "AaronGoodman33", "id": "854692626015993857"}], "urls": [{"start": 197, "end": 220, "url": "https://t.co/0CTFqUnaMk", "expanded_url": "https://twitter.com/KMirza/status/1601008586108174336", "display_url": "twitter.com/KMirza/status/\u2026"}], "hashtags": [{"start": 108, "end": 114, "tag": "ash22"}, {"start": 115, "end": 123, "tag": "ash2022"}]}, "edit_history_tweet_ids": ["1601119499625041923"], "source": "Twitter for Android", "created_at": "2022-12-09T07:40:10.000Z"}, {"text": "In real life we\u2019re friends \ud83d\ude09 \n@AaronGoodman33 @GuiperiniMD @matthew_mei @smalveira23 @chadinabhan where are you? https://t.co/oqJoZwN9Df", "conversation_id": "1601115768598712322", "lang": "en", "author_id": "999010996034338818", "id": "1601115768598712322", "entities": {"mentions": [{"start": 30, "end": 45, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 46, "end": 58, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 59, "end": 71, "username": "matthew_mei", "id": "354168091"}, {"start": 72, "end": 84, "username": "smalveira23", "id": "1125437852836175874"}, {"start": 85, "end": 97, "username": "chadinabhan", "id": "2212735524"}], "urls": [{"start": 113, "end": 136, "url": "https://t.co/oqJoZwN9Df", "expanded_url": "https://twitter.com/ASkarbnik/status/1601115768598712322/photo/1", "display_url": "pic.twitter.com/oqJoZwN9Df", "media_key": "3_1601115763917692931"}]}, "edit_history_tweet_ids": ["1601115768598712322"], "source": "Twitter for iPhone", "created_at": "2022-12-09T07:25:21.000Z"}, {"text": "@AaronGoodman33 What time &amp; how fast? I was gonna do 4 miles around 6 AM; 9:30 min/mile (ish)", "conversation_id": "1601084075368124416", "lang": "en", "author_id": "215681001", "id": "1601098351755558913", "referenced_tweets": [{"type": "replied_to", "id": "1601084075368124416"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "edit_history_tweet_ids": ["1601098351755558913"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for iPhone", "created_at": "2022-12-09T06:16:08.000Z"}, {"text": "Join us this Friday @ASH22 for the Molecular diagnostics &amp; Genomic reclassification of blood cancers scientific workshop. 2-5pm CET Room 298-299 Ernst N Morial Convention Center New Orleans. \ud83d\udd25 line up https://t.co/lEvpUW3Uzk", "conversation_id": "1600254596235960320", "lang": "en", "author_id": "3154223927", "id": "1600254596235960320", "entities": {"mentions": [{"start": 20, "end": 26, "username": "ash22", "id": "18618457"}], "annotations": [{"start": 149, "end": 153, "probability": 0.5094, "type": "Other", "normalized_text": "Ernst"}, {"start": 157, "end": 173, "probability": 0.3822, "type": "Other", "normalized_text": "Morial Convention"}, {"start": 182, "end": 192, "probability": 0.9289, "type": "Place", "normalized_text": "New Orleans"}], "urls": [{"start": 205, "end": 228, "url": "https://t.co/lEvpUW3Uzk", "expanded_url": "https://www.hematology.org/meetings/annual-meeting/programs/friday-scientific-workshops", "display_url": "hematology.org/meetings/annua\u2026", "status": 200, "title": "Scientific Workshops - Hematology.org", "description": "Scientific Workshops", "unwound_url": "https://www.hematology.org/meetings/annual-meeting/programs/friday-scientific-workshops"}]}, "edit_history_tweet_ids": ["1600254596235960320"], "source": "Twitter for iPhone", "created_at": "2022-12-06T22:23:21.000Z"}, {"text": "@chadinabhan @romeerizwan @BldCancerDoc @ninashah33 @Mohty_EBMT @JohnPLeonardMD No one wants a hematologist-oncologist who looks too young!", "conversation_id": "1601020396685660160", "lang": "en", "author_id": "1334487799718961153", "id": "1601036828194533377", "referenced_tweets": [{"type": "replied_to", "id": "1601022306985578496"}], "entities": {"mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 25, "username": "romeerizwan", "id": "15622046"}, {"start": 26, "end": 39, "username": "BldCancerDoc", "id": "2809497047"}, {"start": 40, "end": 51, "username": "ninashah33", "id": "1559241414"}, {"start": 52, "end": 63, "username": "Mohty_EBMT", "id": "2626263112"}, {"start": 64, "end": 79, "username": "JohnPLeonardMD", "id": "2891662867"}]}, "edit_history_tweet_ids": ["1601036828194533377"], "in_reply_to_user_id": "2212735524", "source": "Twitter for iPhone", "created_at": "2022-12-09T02:11:40.000Z"}, {"text": "&gt;56M impressions #ASH22 and it doesn't even officially start till Saturday! \ud83d\ude4c\ud83c\udffb\ud83d\ude4c\ud83c\udffb\n\nLooking forward to representing #PathAtASH soon!\n\nWhere are my fellow #hemepaths at? \ncc: @sanamloghavi \n\nAlso shout out to @hemereports team @Anand_88_Patel @doctorpemm @NitinJainMD #EXCITED https://t.co/d7Ob5IqKSo", "conversation_id": "1601008586108174336", "lang": "en", "author_id": "28108352", "id": "1601008586108174336", "entities": {"mentions": [{"start": 175, "end": 188, "username": "sanamloghavi", "id": "3076847052"}, {"start": 209, "end": 221, "username": "HemeReports", "id": "1481090879536439297"}, {"start": 227, "end": 242, "username": "Anand_88_Patel", "id": "2417458314"}, {"start": 243, "end": 254, "username": "doctorpemm", "id": "2429552622"}, {"start": 255, "end": 267, "username": "NitinJainMD", "id": "2756778469"}], "annotations": [{"start": 21, "end": 25, "probability": 0.424, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 277, "end": 300, "url": "https://t.co/d7Ob5IqKSo", "expanded_url": "https://twitter.com/KMirza/status/1601008586108174336/photo/1", "display_url": "pic.twitter.com/d7Ob5IqKSo", "media_key": "3_1601007536970293252"}], "hashtags": [{"start": 20, "end": 26, "tag": "ASH22"}, {"start": 117, "end": 127, "tag": "PathAtASH"}, {"start": 155, "end": 165, "tag": "hemepaths"}, {"start": 268, "end": 276, "tag": "EXCITED"}]}, "edit_history_tweet_ids": ["1601008586108174336"], "source": "Twitter Web App", "created_at": "2022-12-09T00:19:26.000Z"}, {"text": "Medical conferences would be more fun if it was a 4 day tournament. With winning abstracts advancing each day. So the last day is just the 10-20 best talks. #Ash22", "conversation_id": "1600958272709988352", "lang": "en", "author_id": "1194962714", "id": "1600958272709988352", "entities": {"annotations": [{"start": 158, "end": 162, "probability": 0.4673, "type": "Other", "normalized_text": "Ash22"}], "hashtags": [{"start": 157, "end": 163, "tag": "Ash22"}]}, "edit_history_tweet_ids": ["1600958272709988352"], "source": "Twitter for Android", "created_at": "2022-12-08T20:59:31.000Z"}, {"text": "And look who I find in the taxi line in Nola. \n\nSorry @chadinabhan but you have some competition for @AaronGoodman33 Papa\u2019s affection!  \ud83e\udd17\ud83e\udd17 https://t.co/6W6O4ZpSao https://t.co/3gIH8wMnNa", "conversation_id": "1600982180507049984", "lang": "en", "author_id": "719175246050410496", "id": "1600982180507049984", "referenced_tweets": [{"type": "quoted", "id": "1600900892298907648"}], "entities": {"mentions": [{"start": 54, "end": 66, "username": "chadinabhan", "id": "2212735524"}, {"start": 101, "end": 116, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 40, "end": 43, "probability": 0.6258, "type": "Other", "normalized_text": "Nola"}], "urls": [{"start": 139, "end": 162, "url": "https://t.co/6W6O4ZpSao", "expanded_url": "https://twitter.com/DrAEvens/status/1600982180507049984/photo/1", "display_url": "pic.twitter.com/6W6O4ZpSao", "media_key": "3_1600982173858910224"}, {"start": 163, "end": 186, "url": "https://t.co/3gIH8wMnNa", "expanded_url": "https://twitter.com/aarongoodman33/status/1600900892298907648", "display_url": "twitter.com/aarongoodman33\u2026"}]}, "edit_history_tweet_ids": ["1600982180507049984"], "source": "Twitter for iPhone", "created_at": "2022-12-08T22:34:31.000Z"}, {"text": "@chadinabhan w/ unadulterated man crush on @AaronGoodman33? https://t.co/61MHGTAQRz", "conversation_id": "1600893983668207617", "lang": "en", "author_id": "719175246050410496", "id": "1600893983668207617", "referenced_tweets": [{"type": "quoted", "id": "1600865250374361089"}], "entities": {"mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 43, "end": 58, "username": "AaronGoodman33", "id": "854692626015993857"}], "urls": [{"start": 60, "end": 83, "url": "https://t.co/61MHGTAQRz", "expanded_url": "https://twitter.com/chadinabhan/status/1600865250374361089", "display_url": "twitter.com/chadinabhan/st\u2026"}]}, "edit_history_tweet_ids": ["1600893983668207617"], "in_reply_to_user_id": "2212735524", "source": "Twitter for iPhone", "created_at": "2022-12-08T16:44:03.000Z"}, {"text": "@montypal @AaronGoodman33 @Nirvana @ASkarbnik @sghmd @DocsWhoRock @AleckAmalia @DrRanaMcKay I wouldn\u2019t go to the extreme of super talented \nThat\u2019s an exaggeration.", "conversation_id": "1600865250374361089", "lang": "en", "author_id": "2212735524", "id": "1600933603541942272", "referenced_tweets": [{"type": "replied_to", "id": "1600922844849795072"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "montypal", "id": "24660850"}, {"start": 10, "end": 25, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 26, "end": 34, "username": "Nirvana", "id": "68412310"}, {"start": 35, "end": 45, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 46, "end": 52, "username": "sghmd", "id": "53395744"}, {"start": 53, "end": 65, "username": "DocsWhoRock", "id": "1266013486376726528"}, {"start": 66, "end": 78, "username": "AleckAmalia", "id": "1331336294828437504"}, {"start": 79, "end": 91, "username": "DrRanaMcKay", "id": "1113559627809996801"}]}, "edit_history_tweet_ids": ["1600933603541942272"], "in_reply_to_user_id": "24660850", "source": "Twitter for iPhone", "created_at": "2022-12-08T19:21:29.000Z"}, {"text": "@AaronGoodman33 @ASH_hematology There will be a queue for people wanting to buy you a beer at ASH!", "conversation_id": "1600851981702410240", "lang": "en", "author_id": "149477915", "id": "1600953322940551168", "referenced_tweets": [{"type": "replied_to", "id": "1600851981702410240"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 31, "username": "ASH_hematology", "id": "84072624"}], "annotations": [{"start": 94, "end": 96, "probability": 0.5114, "type": "Organization", "normalized_text": "ASH"}]}, "edit_history_tweet_ids": ["1600953322940551168"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter Web App", "created_at": "2022-12-08T20:39:51.000Z"}, {"text": "Cure means, after a fixed course of therapy, you have the same survival as age sex matched controls\n\nIt doesn't mean MRD neg while taking many drugs, costing 600,000 a year, for the rest of your life, years and years, without proof of OS gain\n\n#ash22\n\nhttps://t.co/JtAniP8cy7", "conversation_id": "1600907726443323392", "lang": "en", "author_id": "1194962714", "id": "1600907726443323392", "entities": {"annotations": [{"start": 117, "end": 119, "probability": 0.7727, "type": "Other", "normalized_text": "MRD"}, {"start": 245, "end": 249, "probability": 0.5851, "type": "Other", "normalized_text": "ash22"}], "urls": [{"start": 252, "end": 275, "url": "https://t.co/JtAniP8cy7", "expanded_url": "https://journals.sagepub.com/doi/abs/10.1177/1049909114524477", "display_url": "journals.sagepub.com/doi/abs/10.117\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1563543025640296452/AYaJ60BC?format=jpg&name=orig", "width": 600, "height": 314}, {"url": "https://pbs.twimg.com/news_img/1563543025640296452/AYaJ60BC?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Use of the Word \u201cCure\u201d in the Oncology Literature - Vinay Prasad, 2015", "description": "Purpose: \u201cCure\u201d is an important word in oncology but its use in the published literature has not been examined. I investigated all oncology articles using cure ...", "unwound_url": "https://journals.sagepub.com/doi/abs/10.1177/1049909114524477"}], "hashtags": [{"start": 244, "end": 250, "tag": "ash22"}]}, "edit_history_tweet_ids": ["1600907726443323392"], "source": "Twitter Web App", "created_at": "2022-12-08T17:38:40.000Z"}, {"text": "First #ASH22 adventure: my checked bag was overweight because of all the protein I packed to consume over the next few days. Still gotta hit the macros when on the road. \ud83d\ude02\ud83c\udfcb\ufe0f\u200d\u2640\ufe0f\ud83d\udcaa", "conversation_id": "1600882405812113408", "lang": "en", "author_id": "53395744", "id": "1600882405812113408", "entities": {"annotations": [{"start": 7, "end": 11, "probability": 0.5701, "type": "Other", "normalized_text": "ASH22"}], "hashtags": [{"start": 6, "end": 12, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1600882405812113408"], "source": "Twitter for iPhone", "created_at": "2022-12-08T15:58:03.000Z"}, {"text": "@chadinabhan @AaronGoodman33 @Nirvana @ASkarbnik @sghmd @DocsWhoRock @montypal @AleckAmalia @DrRanaMcKay I now have \ud83c\udfb6 I\u2019m so happy \ud83c\udfb6 in my head.\n\nWorse ways to start the day.\n\nHow Aaron can utterly disparage Pearl Jam but like the cheap knockoff wannabe PJ Stone Temple Pilots is beyond me, tbh.\n\n\ud83e\udd2b\ud83e\udd73", "conversation_id": "1600865250374361089", "lang": "en", "author_id": "3497730012", "id": "1600881552837091328", "referenced_tweets": [{"type": "replied_to", "id": "1600865250374361089"}], "entities": {"mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 29, "end": 37, "username": "Nirvana", "id": "68412310"}, {"start": 38, "end": 48, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 49, "end": 55, "username": "sghmd", "id": "53395744"}, {"start": 56, "end": 68, "username": "DocsWhoRock", "id": "1266013486376726528"}, {"start": 69, "end": 78, "username": "montypal", "id": "24660850"}, {"start": 79, "end": 91, "username": "AleckAmalia", "id": "1331336294828437504"}, {"start": 92, "end": 104, "username": "DrRanaMcKay", "id": "1113559627809996801"}], "annotations": [{"start": 180, "end": 184, "probability": 0.486, "type": "Other", "normalized_text": "Aaron"}, {"start": 208, "end": 216, "probability": 0.8613, "type": "Other", "normalized_text": "Pearl Jam"}, {"start": 254, "end": 275, "probability": 0.7847, "type": "Other", "normalized_text": "PJ Stone Temple Pilots"}]}, "edit_history_tweet_ids": ["1600881552837091328"], "in_reply_to_user_id": "2212735524", "source": "Twitter for iPad", "created_at": "2022-12-08T15:54:39.000Z"}, {"text": "As you prepare for MRD abstracts at #ASH22, here is our paper that explains how MRD has been used in the last 5 years of #mmsm trials, and the limitations. Thankfully, more \"actionable\" trials on the way!\n\nhttps://t.co/pE5anOaVg9\n\n@rajshekharucms @Eddie_Cliff @AaronGoodman33 https://t.co/pkTzoCVPbe", "conversation_id": "1600868817608925184", "lang": "en", "author_id": "1269642863924609025", "id": "1600868817608925184", "entities": {"mentions": [{"start": 231, "end": 246, "username": "rajshekharucms", "id": "140966169"}, {"start": 247, "end": 259, "username": "Eddie_Cliff", "id": "74081884"}, {"start": 260, "end": 275, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 19, "end": 21, "probability": 0.6415, "type": "Other", "normalized_text": "MRD"}, {"start": 37, "end": 41, "probability": 0.6262, "type": "Other", "normalized_text": "ASH22"}, {"start": 80, "end": 82, "probability": 0.6828, "type": "Other", "normalized_text": "MRD"}, {"start": 122, "end": 125, "probability": 0.5103, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 206, "end": 229, "url": "https://t.co/pE5anOaVg9", "expanded_url": "https://www.nature.com/articles/s41408-022-00750-1", "display_url": "nature.com/articles/s4140\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600868821236998144/O4s59sb6?format=jpg&name=orig", "width": 1970, "height": 1517}, {"url": "https://pbs.twimg.com/news_img/1600868821236998144/O4s59sb6?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015\u20132020", "description": "Blood Cancer Journal - Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015\u20132020", "unwound_url": "https://www.nature.com/articles/s41408-022-00750-1?error=cookies_not_supported&code=5043ea74-3a43-4969-85e8-fa0b6d08d74d"}, {"start": 276, "end": 299, "url": "https://t.co/pkTzoCVPbe", "expanded_url": "https://twitter.com/ManniMD1/status/1600868817608925184/photo/1", "display_url": "pic.twitter.com/pkTzoCVPbe", "media_key": "3_1600868638340239360"}], "hashtags": [{"start": 36, "end": 42, "tag": "ASH22"}, {"start": 121, "end": 126, "tag": "mmsm"}]}, "edit_history_tweet_ids": ["1600868817608925184"], "source": "Twitter Web App", "created_at": "2022-12-08T15:04:03.000Z"}, {"text": "The #HealthcareUnfiltered podcast crashed the party at PAPA @AaronGoodman33 house 2 talk guitar and @Nirvana \nThere was NO #ASH22 talk in this 7 mins video, but it\u2019s the one U must watch on your way 2 the meeting.\n\nUnedited, unfiltered, watch as things evolved.\n\nAnd yes: he sings https://t.co/EhTVwqiTG4", "conversation_id": "1600865250374361089", "lang": "en", "author_id": "2212735524", "id": "1600865250374361089", "entities": {"mentions": [{"start": 60, "end": 75, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 100, "end": 108, "username": "Nirvana", "id": "68412310"}], "annotations": [{"start": 5, "end": 24, "probability": 0.6204, "type": "Other", "normalized_text": "HealthcareUnfiltered"}, {"start": 55, "end": 58, "probability": 0.4415, "type": "Organization", "normalized_text": "PAPA"}, {"start": 124, "end": 128, "probability": 0.6857, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 281, "end": 304, "url": "https://t.co/EhTVwqiTG4", "expanded_url": "https://twitter.com/chadinabhan/status/1600865250374361089/video/1", "display_url": "pic.twitter.com/EhTVwqiTG4", "media_key": "7_1600865073060356097"}], "hashtags": [{"start": 4, "end": 25, "tag": "HealthcareUnfiltered"}, {"start": 123, "end": 129, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1600865250374361089"], "source": "Twitter for iPhone", "created_at": "2022-12-08T14:49:52.000Z"}, {"text": "@AaronGoodman33 How about this one? One of the coolest I saw during my fellowship https://t.co/3MBUTppjjH", "conversation_id": "1600850247185354752", "lang": "en", "author_id": "1144997352148787201", "id": "1600854069664366592", "referenced_tweets": [{"type": "replied_to", "id": "1600850247185354752"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}], "urls": [{"start": 82, "end": 105, "url": "https://t.co/3MBUTppjjH", "expanded_url": "https://ashpublications.org/blood/article/122/14/2302/32191/Lipogranulomatosis-and-hypersplenism-induced-by", "display_url": "ashpublications.org/blood/article/\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600854082486296577/PDZl2PdC?format=png&name=orig", "width": 520, "height": 686}, {"url": "https://pbs.twimg.com/news_img/1600854082486296577/PDZl2PdC?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Lipogranulomatosis and hypersplenism induced by ruptured silicone breast implants", "description": "Amer M. Zeidan, Alison R. Moliterno; Lipogranulomatosis and hypersplenism induced by ruptured silicone breast implants, Blood, Volume 122, Issue 14, 3 October 2", "unwound_url": "https://ashpublications.org/blood/article/122/14/2302/32191/Lipogranulomatosis-and-hypersplenism-induced-by"}]}, "edit_history_tweet_ids": ["1600854069664366592"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for iPhone", "created_at": "2022-12-08T14:05:27.000Z"}, {"text": "@HiraSMian I have full day clinic tomorrow too! \ud83d\ude41", "conversation_id": "1600685500339171330", "lang": "en", "author_id": "1269642863924609025", "id": "1600695160878223360", "referenced_tweets": [{"type": "replied_to", "id": "1600685500339171330"}], "entities": {"mentions": [{"start": 0, "end": 10, "username": "HiraSMian", "id": "419595308"}]}, "edit_history_tweet_ids": ["1600695160878223360"], "in_reply_to_user_id": "419595308", "source": "Twitter Web App", "created_at": "2022-12-08T03:34:00.000Z"}, {"text": "@AaronGoodman33 @MichaelJSlade @CyclingDoctor @LabFehniger @DiPersioLab @ManniMD1 @DavidSteensma @bdermanmd @VincentRK @myelomaMD @Geoff_Uy You mean mastodon?", "conversation_id": "1600642889280798721", "lang": "en", "author_id": "1194962714", "id": "1600694442427502594", "referenced_tweets": [{"type": "replied_to", "id": "1600690511395758081"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 30, "username": "MichaelJSlade", "id": "626650397"}, {"start": 31, "end": 45, "username": "CyclingDoctor", "id": "23036480"}, {"start": 46, "end": 58, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 59, "end": 71, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 72, "end": 81, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 82, "end": 96, "username": "DavidSteensma", "id": "2739065578"}, {"start": 97, "end": 107, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 108, "end": 118, "username": "VincentRK", "id": "24261916"}, {"start": 119, "end": 129, "username": "myelomaMD", "id": "301568235"}, {"start": 130, "end": 139, "username": "Geoff_Uy", "id": "985139345928736768"}], "annotations": [{"start": 149, "end": 156, "probability": 0.661, "type": "Other", "normalized_text": "mastodon"}]}, "edit_history_tweet_ids": ["1600694442427502594"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for Android", "created_at": "2022-12-08T03:31:09.000Z"}, {"text": "As a trainee who\u2019s overwhelmed by the volume of abstracts for #ASH2022, any advice on filtering/reviewing/scheduling from the senior folks?\n\n@CyclingDoctor @LabFehniger @DiPersioLab @AaronGoodman33 @ManniMD1 @DavidSteensma @bdermanmd @VPrasadMDMPH @VincentRK @myelomaMD @Geoff_Uy", "conversation_id": "1600642889280798721", "lang": "en", "author_id": "626650397", "id": "1600642889280798721", "entities": {"mentions": [{"start": 141, "end": 155, "username": "CyclingDoctor", "id": "23036480"}, {"start": 156, "end": 168, "username": "LabFehniger", "id": "1198731683199098881"}, {"start": 169, "end": 181, "username": "DiPersioLab", "id": "1349142172415762433"}, {"start": 182, "end": 197, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 198, "end": 207, "username": "ManniMD1", "id": "1269642863924609025"}, {"start": 208, "end": 222, "username": "DavidSteensma", "id": "2739065578"}, {"start": 223, "end": 233, "username": "bdermanmd", "id": "872983600416862208"}, {"start": 234, "end": 247, "username": "VPrasadMDMPH", "id": "1194962714"}, {"start": 248, "end": 258, "username": "VincentRK", "id": "24261916"}, {"start": 259, "end": 269, "username": "myelomaMD", "id": "301568235"}, {"start": 270, "end": 279, "username": "Geoff_Uy", "id": "985139345928736768"}], "annotations": [{"start": 63, "end": 69, "probability": 0.6243, "type": "Other", "normalized_text": "ASH2022"}], "hashtags": [{"start": 62, "end": 70, "tag": "ASH2022"}]}, "edit_history_tweet_ids": ["1600642889280798721"], "source": "Twitter for iPhone", "created_at": "2022-12-08T00:06:17.000Z"}, {"text": "Like it or not we\u2019re in a significant COVID surge now. Medical meetings should require masks until this wave is over. Docs should lead by example.", "conversation_id": "1600655843313213440", "lang": "en", "author_id": "537795028", "id": "1600655843313213440", "entities": {"annotations": [{"start": 38, "end": 42, "probability": 0.974, "type": "Other", "normalized_text": "COVID"}]}, "edit_history_tweet_ids": ["1600655843313213440"], "source": "Twitter for iPhone", "created_at": "2022-12-08T00:57:46.000Z"}, {"text": "@Dr_AmerZeidan @AaronGoodman33 Though I agree in principle I think what @AaronGoodman33 might be getting at is that these investigators sought to answer these ?\u2019s and they did so by well designed randomized studies. This does not, however, answer relevant clinical ?\u2019s like the ones I outlined in my responses.", "conversation_id": "1600519646028869633", "lang": "en", "author_id": "782764410", "id": "1600617014053183491", "referenced_tweets": [{"type": "replied_to", "id": "1600605663356456962"}], "entities": {"mentions": [{"start": 0, "end": 14, "username": "Dr_AmerZeidan", "id": "1144997352148787201"}, {"start": 15, "end": 30, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 72, "end": 87, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "edit_history_tweet_ids": ["1600617014053183491"], "in_reply_to_user_id": "1144997352148787201", "source": "Twitter for iPhone", "created_at": "2022-12-07T22:23:28.000Z"}, {"text": "The title of my talk today to rheumatologists, we are already changing practice and minds as a result of the amazing work by @iStopMM @sykristinsson \n\nhttps://t.co/6Fok0TBUDi\n\nAn example of practice changed even before the actual #ASH22 meeting! https://t.co/QUlXawKR7Z", "conversation_id": "1600545405540126720", "lang": "en", "author_id": "1269642863924609025", "id": "1600545405540126720", "entities": {"mentions": [{"start": 125, "end": 133, "username": "iStopMM", "id": "844232399319941122"}, {"start": 134, "end": 148, "username": "sykristinsson", "id": "3078258341"}], "annotations": [{"start": 231, "end": 235, "probability": 0.6187, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 151, "end": 174, "url": "https://t.co/6Fok0TBUDi", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper169393.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: adult, Research, epidemiology, Plasma Cell Disorders, Clinical Research, Diseases, Lymphoid Malignancies, Human, Study Population Ingigerdur S Sverrisdottir, MD 1,2 *, Sigr\u00fan Thorsteinsd\u00f3ttir, MD, PhD 2,3, S\u00e6mundur R\u00f6gnvaldsson, MD 4 *, Thor Aspelund, PhD 2 *, Brynjar Vidarsson, MD 5, P\u00e1ll Torfi \u00d6nundarson, MD 5 *, Bjarni Agnarsson, MD", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper169393.html"}, {"start": 246, "end": 269, "url": "https://t.co/QUlXawKR7Z", "expanded_url": "https://twitter.com/ManniMD1/status/1600545405540126720/photo/1", "display_url": "pic.twitter.com/QUlXawKR7Z", "media_key": "3_1600545179307425792"}], "hashtags": [{"start": 230, "end": 236, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1600545405540126720"], "source": "Twitter Web App", "created_at": "2022-12-07T17:38:56.000Z"}, {"text": "#ASH22 Practice Changers\n\nTime to abolish for good the neutropenic diet!\nLet patients with cancer eat what ever they want even if neutropenic.\n\nRCT in HSCT or induction chemo pts\nRandomized 1:1 to standard diet or protective diet.\n\nNo difference in infections! https://t.co/sKNJ3DN7sU https://t.co/ewKqTmAQ1u", "conversation_id": "1600261398268764160", "lang": "en", "author_id": "854692626015993857", "id": "1600261398268764160", "referenced_tweets": [{"type": "quoted", "id": "1599925397139099648"}], "entities": {"annotations": [{"start": 1, "end": 5, "probability": 0.6249, "type": "Other", "normalized_text": "ASH22"}, {"start": 151, "end": 154, "probability": 0.7166, "type": "Other", "normalized_text": "HSCT"}], "urls": [{"start": 261, "end": 284, "url": "https://t.co/sKNJ3DN7sU", "expanded_url": "https://twitter.com/AaronGoodman33/status/1600261398268764160/photo/1", "display_url": "pic.twitter.com/sKNJ3DN7sU", "media_key": "3_1600260629113077760"}, {"start": 285, "end": 308, "url": "https://t.co/ewKqTmAQ1u", "expanded_url": "https://twitter.com/AaronGoodman33/status/1599925397139099648", "display_url": "twitter.com/AaronGoodman33\u2026"}], "hashtags": [{"start": 0, "end": 6, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1600261398268764160"], "source": "Twitter Web App", "created_at": "2022-12-06T22:50:23.000Z"}, {"text": "The presence or absence of gain1q did not change outcomes in a cohort of patients with relapsed myeloma receiving daratumumab- data from the Mayo dataset.\n\nIMO- Anti-CD38 therapy similarly effective in gain1q, whether you choose isa or dara. \n\nhttps://t.co/hMfWRSn6tN\n\n#ASH22", "conversation_id": "1600478408659517440", "lang": "en", "author_id": "1269642863924609025", "id": "1600478408659517440", "entities": {"annotations": [{"start": 96, "end": 102, "probability": 0.6041, "type": "Other", "normalized_text": "myeloma"}, {"start": 114, "end": 124, "probability": 0.4996, "type": "Other", "normalized_text": "daratumumab"}, {"start": 141, "end": 144, "probability": 0.4638, "type": "Other", "normalized_text": "Mayo"}, {"start": 165, "end": 165, "probability": 0.5268, "type": "Other", "normalized_text": "-"}], "urls": [{"start": 244, "end": 267, "url": "https://t.co/hMfWRSn6tN", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper169533.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II Ricardo D Parrondo, MD 1, Lindsay Brooke Gardner, MS, MD 1, Mohamad Alhaj Moustafa, MD 1, Vivek Roy, MD 2, Taimur Sher, MD 1, Ahsan Rasheed 2 *, Rahma M Warsame, MD 3, Jeremy T. Larsen 4 *, Wilson I. Gonsalves, MD 5, Taxiarchis Kourelis, MD 5, Prashant Kapoor, MD 3, Rafael Fonseca, MD 4, Asher Chanan-Khan, MD 2 and Sikander Ailawadhi 6 1 Division of Hematology and Medical", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper169533.html"}], "hashtags": [{"start": 269, "end": 275, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1600478408659517440"], "source": "Twitter Web App", "created_at": "2022-12-07T13:12:42.000Z"}, {"text": "Interesting study in @BloodAdvances but are you treating MYC-only translocated NHL with non-RCHOP program?\n@ASkarbnik @GuiperiniMD @AaronGoodman33 \n\nhttps://t.co/5sw3fwWNsx+\u00bb&amp;utm_id=212692&amp;sfmc_id=19415589", "conversation_id": "1600467379158294528", "lang": "en", "author_id": "2212735524", "id": "1600467379158294528", "entities": {"mentions": [{"start": 21, "end": 35, "username": "BloodAdvances", "id": "732570175162179585"}, {"start": 107, "end": 117, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 118, "end": 130, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 131, "end": 146, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 57, "end": 59, "probability": 0.5132, "type": "Organization", "normalized_text": "MYC"}, {"start": 79, "end": 81, "probability": 0.7652, "type": "Organization", "normalized_text": "NHL"}, {"start": 92, "end": 96, "probability": 0.5451, "type": "Other", "normalized_text": "RCHOP"}], "urls": [{"start": 149, "end": 172, "url": "https://t.co/5sw3fwWNsx", "expanded_url": "https://ashpublications.org/bloodadvances/article/6/22/5811/485287/Safety-and-efficacy-of-a-dose-dense-short-term?utm_source=&utm_medium=&utm_campaign=highlights_12_6_22&utm_source=sfmc&utm_medium=email&utm_campaign=BA+Highlights_12_6_22&utm_term=Link+Text", "display_url": "ashpublications.org/bloodadvances/\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1599788273773121537/xXGO_tPi?format=png&name=orig", "width": 520, "height": 685}, {"url": "https://pbs.twimg.com/news_img/1599788273773121537/xXGO_tPi?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma", "description": "Key Points. CARMEN regimen includes single doses of drugs delivered in 81 days (median), with good tolerability and lower risk of late toxicity.A 5-year OS of \u223c", "unwound_url": "https://ashpublications.org/bloodadvances/article/6/22/5811/485287/Safety-and-efficacy-of-a-dose-dense-short-term?utm_source=&utm_medium=&utm_campaign=highlights_12_6_22&utm_source=sfmc&utm_medium=email&utm_campaign=BA+Highlights_12_6_22&utm_term=Link+Text"}]}, "edit_history_tweet_ids": ["1600467379158294528"], "source": "Twitter for iPhone", "created_at": "2022-12-07T12:28:53.000Z"}, {"text": "Of the many miseries endured by patients  in the hospital one of them is the needlessly restrictive diet \ud83d\udc47\ud83c\udffb p.o. &gt; ANC https://t.co/I6Wg2rP9n7", "conversation_id": "1600283901821583360", "lang": "en", "author_id": "807337182", "id": "1600283901821583360", "referenced_tweets": [{"type": "quoted", "id": "1600261398268764160"}], "entities": {"annotations": [{"start": 118, "end": 120, "probability": 0.8958, "type": "Organization", "normalized_text": "ANC"}], "urls": [{"start": 122, "end": 145, "url": "https://t.co/I6Wg2rP9n7", "expanded_url": "https://twitter.com/AaronGoodman33/status/1600261398268764160", "display_url": "twitter.com/AaronGoodman33\u2026"}]}, "edit_history_tweet_ids": ["1600283901821583360"], "source": "Twitter for iPhone", "created_at": "2022-12-07T00:19:48.000Z"}, {"text": "@ManniMD1 But perhaps the only true cure?", "conversation_id": "1600320621426397184", "lang": "en", "author_id": "854692626015993857", "id": "1600321063426326528", "referenced_tweets": [{"type": "replied_to", "id": "1600320621426397184"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}]}, "edit_history_tweet_ids": ["1600321063426326528"], "in_reply_to_user_id": "1269642863924609025", "source": "Twitter for iPhone", "created_at": "2022-12-07T02:47:28.000Z"}, {"text": "Good reminder of limited role of allogenic transplant in multiple myeloma- Mayo Clinic experience\n\nN=89\nLong term survival in less than 20%\nBy 2 years, 75% pts either progressed or died\n\nCaveat:most patients at relapse, not 1st remission\n\nhttps://t.co/TRmA2IIBMa\n\n#mmsm \n#ASH22 https://t.co/KDYAfJRqgU", "conversation_id": "1600320621426397184", "lang": "en", "author_id": "1269642863924609025", "id": "1600320621426397184", "entities": {"annotations": [{"start": 66, "end": 85, "probability": 0.6851, "type": "Other", "normalized_text": "myeloma- Mayo Clinic"}, {"start": 265, "end": 268, "probability": 0.4892, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 239, "end": 262, "url": "https://t.co/TRmA2IIBMa", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper156078.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Outcomes of Allogeneic Stem Cell Transplant for Multiple Myeloma", "description": "Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster II Hematology Disease Topics & Pathways: Research, Biological therapies, Clinical Research, health outcomes research, Therapies, Transplantation 1 Mayo Clinic Alix School of Medicine, Rochester, MN 2 Mayo clinic college of medicine, Rochester, MN 3 Division of Hematology, Mayo Clinic, Rochester, MN 4 Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper156078.html"}, {"start": 278, "end": 301, "url": "https://t.co/KDYAfJRqgU", "expanded_url": "https://twitter.com/ManniMD1/status/1600320621426397184/photo/1", "display_url": "pic.twitter.com/KDYAfJRqgU", "media_key": "3_1600320617927958528"}], "hashtags": [{"start": 264, "end": 269, "tag": "mmsm"}, {"start": 271, "end": 277, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1600320621426397184"], "source": "Twitter for iPhone", "created_at": "2022-12-07T02:45:43.000Z"}, {"text": "@acweyand Per @AleckAmalia Cafe Du Monde.  I will be going their daily.", "conversation_id": "1600313165601857539", "lang": "en", "author_id": "854692626015993857", "id": "1600320182240522240", "referenced_tweets": [{"type": "replied_to", "id": "1600313165601857539"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "acweyand", "id": "824315782947631104"}, {"start": 14, "end": 26, "username": "AleckAmalia", "id": "1331336294828437504"}], "annotations": [{"start": 27, "end": 39, "probability": 0.877, "type": "Other", "normalized_text": "Cafe Du Monde"}]}, "edit_history_tweet_ids": ["1600320182240522240"], "in_reply_to_user_id": "824315782947631104", "source": "Twitter for iPhone", "created_at": "2022-12-07T02:43:58.000Z"}, {"text": "But seriously, the most important questions re: #ASH22 are where are the best beignets in New Orleans and how many times a day is acceptable to eat them?", "conversation_id": "1600313165601857539", "lang": "en", "author_id": "824315782947631104", "id": "1600313165601857539", "entities": {"annotations": [{"start": 49, "end": 53, "probability": 0.7102, "type": "Other", "normalized_text": "ASH22"}, {"start": 90, "end": 100, "probability": 0.992, "type": "Place", "normalized_text": "New Orleans"}], "hashtags": [{"start": 48, "end": 54, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1600313165601857539"], "source": "Twitter for iPhone", "created_at": "2022-12-07T02:16:05.000Z"}, {"text": "@AaronGoodman33 @PapaemmanuilLab @ash22 Same!", "conversation_id": "1600254596235960320", "lang": "en", "author_id": "18821994", "id": "1600297330946678784", "referenced_tweets": [{"type": "replied_to", "id": "1600296136417619968"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 32, "username": "PapaemmanuilLab", "id": "3154223927"}, {"start": 33, "end": 39, "username": "ash22", "id": "18618457"}]}, "edit_history_tweet_ids": ["1600297330946678784"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for iPhone", "created_at": "2022-12-07T01:13:10.000Z"}, {"text": "When a recommendation from a knowledgeable oncologist to treat a myeloma patient with maintenance using Daratumumab alternating with Isatuximab (to overcome 1q and decrease the incidence of resistance)! Then all I have to say this is a different level of BS! #mmsm", "conversation_id": "1600296085209202688", "lang": "en", "author_id": "1026947037080772610", "id": "1600296085209202688", "entities": {"annotations": [{"start": 65, "end": 71, "probability": 0.5885, "type": "Other", "normalized_text": "myeloma"}, {"start": 104, "end": 114, "probability": 0.8093, "type": "Other", "normalized_text": "Daratumumab"}, {"start": 133, "end": 142, "probability": 0.8277, "type": "Other", "normalized_text": "Isatuximab"}, {"start": 260, "end": 263, "probability": 0.5008, "type": "Other", "normalized_text": "mmsm"}], "hashtags": [{"start": 259, "end": 264, "tag": "mmsm"}]}, "edit_history_tweet_ids": ["1600296085209202688"], "source": "Twitter for iPhone", "created_at": "2022-12-07T01:08:13.000Z"}, {"text": "#ASH22 Practice Changers\n\nTriangle study!\n\nFrontline Mantle Cell\nTransplant eligible\n\n3 arms*\nRCHOP/DHAP + ibrutinib-&gt;I maint\nRCHOP/DHAP + I-&gt;ASCT-&gt;I maint\nRCHOP/DHAP-&gt;ASCT\n*ritux maint allowed\n\nFFS equal in ibrutinib arms regardless of ASCT or not\n\nCan \ud83d\udeabASCT if ibrutinib used https://t.co/btoPwYi8KK https://t.co/pG7exZwa7f", "conversation_id": "1599925397139099648", "lang": "en", "author_id": "854692626015993857", "id": "1599925397139099648", "referenced_tweets": [{"type": "quoted", "id": "1599093726345056256"}], "entities": {"annotations": [{"start": 53, "end": 63, "probability": 0.5267, "type": "Other", "normalized_text": "Mantle Cell"}, {"start": 94, "end": 98, "probability": 0.5004, "type": "Other", "normalized_text": "RCHOP"}, {"start": 100, "end": 103, "probability": 0.5465, "type": "Other", "normalized_text": "DHAP"}, {"start": 107, "end": 115, "probability": 0.5074, "type": "Other", "normalized_text": "ibrutinib"}, {"start": 129, "end": 133, "probability": 0.505, "type": "Other", "normalized_text": "RCHOP"}, {"start": 135, "end": 138, "probability": 0.4628, "type": "Other", "normalized_text": "DHAP"}, {"start": 165, "end": 169, "probability": 0.481, "type": "Other", "normalized_text": "RCHOP"}, {"start": 171, "end": 174, "probability": 0.508, "type": "Other", "normalized_text": "DHAP"}, {"start": 275, "end": 283, "probability": 0.5558, "type": "Other", "normalized_text": "ibrutinib"}], "urls": [{"start": 290, "end": 313, "url": "https://t.co/btoPwYi8KK", "expanded_url": "https://twitter.com/AaronGoodman33/status/1599925397139099648/photo/1", "display_url": "pic.twitter.com/btoPwYi8KK", "media_key": "3_1599925066690502656"}, {"start": 314, "end": 337, "url": "https://t.co/pG7exZwa7f", "expanded_url": "https://twitter.com/AaronGoodman33/status/1599093726345056256", "display_url": "twitter.com/AaronGoodman33\u2026"}], "hashtags": [{"start": 0, "end": 6, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1599925397139099648"], "source": "Twitter Web App", "created_at": "2022-12-06T00:35:14.000Z"}, {"text": "@matthew_mei @GuiperiniMD @paulocruzphi Don\u2019t mind @GuiperiniMD , he only pretends he knows music, while thinking that Eagles is the best band ever.", "conversation_id": "1599065279786409985", "lang": "en", "author_id": "999010996034338818", "id": "1600202096393224193", "referenced_tweets": [{"type": "replied_to", "id": "1600201643785539584"}], "entities": {"mentions": [{"start": 0, "end": 12, "username": "matthew_mei", "id": "354168091"}, {"start": 13, "end": 25, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 26, "end": 39, "username": "paulocruzphi", "id": "1913011345"}, {"start": 51, "end": 63, "username": "GuiperiniMD", "id": "1294745239656202240"}], "annotations": [{"start": 119, "end": 124, "probability": 0.9125, "type": "Organization", "normalized_text": "Eagles"}]}, "edit_history_tweet_ids": ["1600202096393224193"], "in_reply_to_user_id": "354168091", "source": "Twitter for iPhone", "created_at": "2022-12-06T18:54:44.000Z"}, {"text": "@ASkarbnik @AaronGoodman33 @GuiperiniMD Either of you guys there on Thurs?", "conversation_id": "1599925397139099648", "lang": "en", "author_id": "354168091", "id": "1599947443327893504", "referenced_tweets": [{"type": "replied_to", "id": "1599946249528291330"}], "entities": {"mentions": [{"start": 0, "end": 10, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 11, "end": 26, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 27, "end": 39, "username": "GuiperiniMD", "id": "1294745239656202240"}], "annotations": [{"start": 68, "end": 72, "probability": 0.5503, "type": "Other", "normalized_text": "Thurs"}]}, "edit_history_tweet_ids": ["1599947443327893504"], "in_reply_to_user_id": "999010996034338818", "source": "Twitter Web App", "created_at": "2022-12-06T02:02:50.000Z"}, {"text": "@matthew_mei @GuiperiniMD @ASkarbnik This study gets rid of one toxic therapy (auto) and replaces with something else.  SHINE just adds therapy we know works.\n\nNeither are truly practice changing if you read my attached tweet although this study better than SHINE which just confirmed the obvious.", "conversation_id": "1599925397139099648", "lang": "en", "author_id": "854692626015993857", "id": "1599942610046824449", "referenced_tweets": [{"type": "replied_to", "id": "1599941573659463680"}], "entities": {"mentions": [{"start": 0, "end": 12, "username": "matthew_mei", "id": "354168091"}, {"start": 13, "end": 25, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 26, "end": 36, "username": "ASkarbnik", "id": "999010996034338818"}], "annotations": [{"start": 258, "end": 262, "probability": 0.7584, "type": "Other", "normalized_text": "SHINE"}]}, "edit_history_tweet_ids": ["1599942610046824449"], "in_reply_to_user_id": "354168091", "source": "Twitter for iPhone", "created_at": "2022-12-06T01:43:38.000Z"}, {"text": "@GuiperiniMD @ASkarbnik @AaronGoodman33 Haha -- yeah, SHINE got trashed and this is plenary.  Make it make sense", "conversation_id": "1599925397139099648", "lang": "en", "author_id": "354168091", "id": "1599941573659463680", "referenced_tweets": [{"type": "replied_to", "id": "1599941390443479041"}], "entities": {"mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 13, "end": 23, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 24, "end": 39, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 54, "end": 58, "probability": 0.6184, "type": "Other", "normalized_text": "SHINE"}]}, "edit_history_tweet_ids": ["1599941573659463680"], "in_reply_to_user_id": "1294745239656202240", "source": "Twitter Web App", "created_at": "2022-12-06T01:39:31.000Z"}, {"text": "@AaronGoodman33 Where does HyperCVAD / HDmtx-HD-cyt factor in?  Is that better than the outpatient recipe, or the same?  And what about other BTK inhibitors that \"may\" be safer than Ibrutinib?", "conversation_id": "1599925397139099648", "lang": "en", "author_id": "2170420038", "id": "1599930810962182144", "referenced_tweets": [{"type": "replied_to", "id": "1599925397139099648"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 27, "end": 35, "probability": 0.7703, "type": "Other", "normalized_text": "HyperCVAD"}, {"start": 39, "end": 43, "probability": 0.4938, "type": "Other", "normalized_text": "HDmtx"}, {"start": 142, "end": 144, "probability": 0.4184, "type": "Organization", "normalized_text": "BTK"}, {"start": 182, "end": 190, "probability": 0.6879, "type": "Other", "normalized_text": "Ibrutinib"}]}, "edit_history_tweet_ids": ["1599930810962182144"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter Web App", "created_at": "2022-12-06T00:56:45.000Z"}, {"text": "@AaronGoodman33 And BR + ASCT looks similar to R-CHOP / R-DHAP + ASCT ... by the transitive property then BR + ibrutinib wins right?  So SHINE after all?  (Btw this is in jest obviously)  https://t.co/KQS9Cxbfig", "conversation_id": "1599925397139099648", "lang": "en", "author_id": "354168091", "id": "1599929906628284416", "referenced_tweets": [{"type": "replied_to", "id": "1599925397139099648"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 58, "end": 61, "probability": 0.3818, "type": "Other", "normalized_text": "DHAP"}, {"start": 111, "end": 119, "probability": 0.4918, "type": "Other", "normalized_text": "ibrutinib"}], "urls": [{"start": 188, "end": 211, "url": "https://t.co/KQS9Cxbfig", "expanded_url": "https://ashpublications.org/bloodadvances/article/6/18/5285/484992/Bendamustine-or-high-dose-cytarabine-based", "display_url": "ashpublications.org/bloodadvances/\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1599929916271005696/ZfuMNMfg?format=png&name=orig", "width": 520, "height": 681}, {"url": "https://pbs.twimg.com/news_img/1599929916271005696/ZfuMNMfg?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma", "description": "Key Points. R-B with ASCT and MR is a feasible first-line strategy for younger, transplant-eligible patients with MCL.R-B with ASCT and MR achieves outcomes com", "unwound_url": "https://ashpublications.org/bloodadvances/article/6/18/5285/484992/Bendamustine-or-high-dose-cytarabine-based"}]}, "edit_history_tweet_ids": ["1599929906628284416"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter Web App", "created_at": "2022-12-06T00:53:09.000Z"}, {"text": "I will be sharing over next few days #ASH22 abstracts that are practice changing for me! \n\nBMTCTN 1703 by legendary bassist @sghmd \n\nRIC sib/MUD allo\nPeripheral blood donor\nPTCy/Tac/MMF vs Tac/MTX \n\n1-yr GRFS 52.7% for PTCy vs 34.9%\n\u2b07\ufe0facute+chronic GVHD! \n\nhttps://t.co/2MZgWt2YNT https://t.co/4UvkuJsdY2", "conversation_id": "1598728138812710912", "lang": "en", "author_id": "854692626015993857", "id": "1598728138812710912", "entities": {"mentions": [{"start": 124, "end": 130, "username": "sghmd", "id": "53395744"}], "annotations": [{"start": 38, "end": 42, "probability": 0.5499, "type": "Other", "normalized_text": "ASH22"}, {"start": 91, "end": 96, "probability": 0.6744, "type": "Other", "normalized_text": "BMTCTN"}], "urls": [{"start": 257, "end": 280, "url": "https://t.co/2MZgWt2YNT", "expanded_url": "https://tinyurl.com/5n7vunmn", "display_url": "tinyurl.com/5n7vunmn", "status": 200, "title": "Paper: Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703", "description": "Program: General Sessions Session: Late-Breaking Abstracts Session Hematology Disease Topics & Pathways: adult, Research, clinical trials, Non-Biological therapies, Clinical Research, Chemotherapy, Therapies, immunology, Adverse Events, Biological Processes, Human, Study Population Shernan G Holtan, MD 1, Mehdi Hamadani, MD 2, Juan WU 3 *, Monzr M. AL Malki, MD 4, Lyndsey Runaas, MD 5 *, Hany Elmariah, MD, MS 6, Andrew R. Rezvani, MD 7, Mahasweta Gooptu, MD 8, Karilyn T. Larkin, MD 9, Brian C. Shaffer, MD", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper171463.html"}, {"start": 281, "end": 304, "url": "https://t.co/4UvkuJsdY2", "expanded_url": "https://twitter.com/AaronGoodman33/status/1598728138812710912/photo/1", "display_url": "pic.twitter.com/4UvkuJsdY2", "media_key": "3_1598727191889469440"}], "hashtags": [{"start": 37, "end": 43, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1598728138812710912"], "source": "Twitter Web App", "created_at": "2022-12-02T17:17:45.000Z"}, {"text": "#ASH22 Practice Changers\n\nE1910 @MartinTallman\n\nPh- B-ALL (30-70 yo) \nBFM-like induction [PEG if&lt;55 yo,ritux if CD20+]\n\ns/p intensification MRD-(&lt;0.01%) randomized to blinatumomab+chemo vs chemo\nBlina arm superior OS\n\nMy practice = blina for MRD+ and MRD-\n\nhttps://t.co/SMATmfygre https://t.co/sKerPuX21E https://t.co/fiIEslO14i", "conversation_id": "1599093726345056256", "lang": "en", "author_id": "854692626015993857", "id": "1599093726345056256", "referenced_tweets": [{"type": "quoted", "id": "1598728138812710912"}], "entities": {"mentions": [{"start": 32, "end": 46, "username": "MartinTallman", "id": "1334487799718961153"}], "annotations": [{"start": 173, "end": 184, "probability": 0.5868, "type": "Other", "normalized_text": "blinatumomab"}, {"start": 201, "end": 205, "probability": 0.4542, "type": "Other", "normalized_text": "Blina"}], "urls": [{"start": 263, "end": 286, "url": "https://t.co/SMATmfygre", "expanded_url": "https://tinyurl.com/4kapaavz", "display_url": "tinyurl.com/4kapaavz", "status": 200, "title": "Paper: Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Networ", "description": "Program: General Sessions Session: Late-Breaking Abstracts Session Hematology Disease Topics & Pathways: ALL, Biological therapies, Lymphoid Leukemias, Clinical Practice (Health Services and Quality), Bispecific Antibody Therapy, Diseases, Therapies, Lymphoid Malignancies 1 Division of Hemat ology, Mayo Clinic, Rochester, MN 2 Dana-Farber Cancer Institute, Boston, MA 3 Cancer Center, Montefiore Medical Center, Bronx, NY 4 Carbone Comprehensive Cancer Center, Madison, WI 5 Adult Hematologic Malignancies &", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper171751.html"}, {"start": 287, "end": 310, "url": "https://t.co/sKerPuX21E", "expanded_url": "https://twitter.com/AaronGoodman33/status/1599093726345056256/photo/1", "display_url": "pic.twitter.com/sKerPuX21E", "media_key": "3_1599091253223645184"}, {"start": 311, "end": 334, "url": "https://t.co/fiIEslO14i", "expanded_url": "https://twitter.com/AaronGoodman33/status/1598728138812710912", "display_url": "twitter.com/AaronGoodman33\u2026"}], "hashtags": [{"start": 0, "end": 6, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1599093726345056256"], "source": "Twitter Web App", "created_at": "2022-12-03T17:30:28.000Z"}, {"text": "#ASH22 starts this week.\n\nHere is a list of top 10 abstracts that have already influenced my thought and practice in myeloma! Look forward to hearing more about these and other studies at the meeting!\n\n#mmsm https://t.co/mmiGmXbiUG", "conversation_id": "1599779550753193985", "lang": "en", "author_id": "1269642863924609025", "id": "1599779550753193985", "referenced_tweets": [{"type": "quoted", "id": "1590440063263182851"}], "entities": {"annotations": [{"start": 1, "end": 5, "probability": 0.6643, "type": "Other", "normalized_text": "ASH22"}, {"start": 117, "end": 123, "probability": 0.7147, "type": "Other", "normalized_text": "myeloma"}, {"start": 203, "end": 206, "probability": 0.4725, "type": "Other", "normalized_text": "mmsm"}], "urls": [{"start": 208, "end": 231, "url": "https://t.co/mmiGmXbiUG", "expanded_url": "https://twitter.com/ManniMD1/status/1590440063263182851", "display_url": "twitter.com/ManniMD1/statu\u2026"}], "hashtags": [{"start": 0, "end": 6, "tag": "ASH22"}, {"start": 202, "end": 207, "tag": "mmsm"}]}, "edit_history_tweet_ids": ["1599779550753193985"], "source": "Twitter Web App", "created_at": "2022-12-05T14:55:42.000Z"}, {"text": "@AaronGoodman33 Cancer groups would be stronger if they actually addressed some of the legitimate criticism about the high price, and skewed research agenda. Hope they do!", "conversation_id": "1599859955275735040", "lang": "en", "author_id": "1194962714", "id": "1599872039862824960", "referenced_tweets": [{"type": "replied_to", "id": "1599868146663690240"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "edit_history_tweet_ids": ["1599872039862824960"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for Android", "created_at": "2022-12-05T21:03:13.000Z"}, {"text": "It was great to get this feedback from the packed auditorium for the UK Myeloma Research day\ud83d\udc47\ud83d\udc47\n\nBecause of the magic of technology, you can watch the lecture they heard! \n\nIn case interested, I would be happy to debate any of the arguments in the vid\nhttps://t.co/bVnafQJHvg https://t.co/kGzDBr3xog", "conversation_id": "1599859955275735040", "lang": "en", "author_id": "1194962714", "id": "1599859955275735040", "entities": {"annotations": [{"start": 69, "end": 70, "probability": 0.7695, "type": "Place", "normalized_text": "UK"}, {"start": 72, "end": 87, "probability": 0.6183, "type": "Other", "normalized_text": "Myeloma Research"}], "urls": [{"start": 251, "end": 274, "url": "https://t.co/bVnafQJHvg", "expanded_url": "https://www.youtube.com/watch?v=jAz84yCnfjQ&t=22", "display_url": "youtube.com/watch?v=jAz84y\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1599859959172210688/ES5stYKW?format=jpg&name=orig", "width": 1280, "height": 720}, {"url": "https://pbs.twimg.com/news_img/1599859959172210688/ES5stYKW?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "What Questions are Current Myeloma Trials NOT Answering | Invited Talk to UK Myeloma Research Day", "description": "A link to our paper that I didn't mention but should havehttps://ashpublications.org/blood/article/137/4/456/474255/Persistent-challenges-with-treating-multi...", "unwound_url": "https://www.youtube.com/watch?v=jAz84yCnfjQ&t=22"}, {"start": 275, "end": 298, "url": "https://t.co/kGzDBr3xog", "expanded_url": "https://twitter.com/VPrasadMDMPH/status/1599859955275735040/photo/1", "display_url": "pic.twitter.com/kGzDBr3xog", "media_key": "3_1599859502668316672"}]}, "edit_history_tweet_ids": ["1599859955275735040"], "source": "Twitter Web App", "created_at": "2022-12-05T20:15:11.000Z"}, {"text": "You were right @AaronGoodman33 \n\nThe DM was pure optics- nothing productive came out of it. @Optum took the weekend off, while our patients with cancer stayed in a limbo about whether their necessary treatment would be approved or not. https://t.co/WtFwkcYCg1", "conversation_id": "1599826784786477057", "lang": "en", "author_id": "1269642863924609025", "id": "1599826784786477057", "referenced_tweets": [{"type": "quoted", "id": "1598819684610347014"}], "entities": {"mentions": [{"start": 15, "end": 30, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 92, "end": 98, "username": "Optum", "id": "318007077"}], "annotations": [{"start": 145, "end": 150, "probability": 0.4904, "type": "Other", "normalized_text": "cancer"}], "urls": [{"start": 236, "end": 259, "url": "https://t.co/WtFwkcYCg1", "expanded_url": "https://twitter.com/AaronGoodman33/status/1598819684610347014", "display_url": "twitter.com/AaronGoodman33\u2026"}]}, "edit_history_tweet_ids": ["1599826784786477057"], "source": "Twitter Web App", "created_at": "2022-12-05T18:03:23.000Z"}, {"text": "Looking for an A+  hematology clinician investigator job in Boston?  We would love to hear from you. Graduating fellows welcome. \n\nhttps://t.co/lZqeaSsSto\n\n For residents considering heme/onc fellowship, our section needs hospitalists!  Great mentoring \n\nhttps://t.co/ReQtvLr9PM", "conversation_id": "1599787532568252422", "lang": "en", "author_id": "1578929666", "id": "1599787532568252422", "entities": {"annotations": [{"start": 60, "end": 65, "probability": 0.9762, "type": "Place", "normalized_text": "Boston"}], "urls": [{"start": 131, "end": 154, "url": "https://t.co/lZqeaSsSto", "expanded_url": "https://tinyurl.com/542c5wx3", "display_url": "tinyurl.com/542c5wx3", "unwound_url": "https://bu.silkroad.com/epostings/index.cfm?fuseaction=app.jobinfo&id=23&jobid=311032&company_id=15509&version=1&source=ONLINE&JobOwner=1016383&level=levelid2&levelid2=20820&startflag=3"}, {"start": 255, "end": 278, "url": "https://t.co/ReQtvLr9PM", "expanded_url": "https://tinyurl.com/2p8xwczn", "display_url": "tinyurl.com/2p8xwczn", "unwound_url": "https://bu.silkroad.com/epostings/index.cfm?fuseaction=app.jobinfo&id=23&jobid=310918&company_id=15509&version=1&source=ONLINE&JobOwner=1016383&level=levelid2&levelid2=20820&startflag=3"}]}, "edit_history_tweet_ids": ["1599787532568252422"], "source": "Twitter for iPhone", "created_at": "2022-12-05T15:27:25.000Z"}, {"text": "@AaronGoodman33 Let us know how it is once you\u2019re done! I\u2019ve been wanting to read it", "conversation_id": "1599557478538043394", "lang": "en", "author_id": "1126106500701806592", "id": "1599578871611158530", "referenced_tweets": [{"type": "replied_to", "id": "1599557478538043394"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "edit_history_tweet_ids": ["1599578871611158530"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for iPhone", "created_at": "2022-12-05T01:38:16.000Z"}, {"text": "@AaronGoodman33 I take responsibility for recommending it. I love the book. And if people disagree i am happy to debate them.", "conversation_id": "1599557478538043394", "lang": "en", "author_id": "1194962714", "id": "1599560167322181632", "referenced_tweets": [{"type": "replied_to", "id": "1599557478538043394"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "edit_history_tweet_ids": ["1599560167322181632"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter Web App", "created_at": "2022-12-05T00:23:56.000Z"}, {"text": "Is it fair for us to politely ask (without disrespecting the people being interviewed) who pays @TargetedOnc for this content?\n\nIs it fair to ask them to report money they received from Karyopharm (if any) for this?\n\nhttps://t.co/lY1whIeggs", "conversation_id": "1599445097224892418", "lang": "en", "author_id": "1269642863924609025", "id": "1599445097224892418", "entities": {"mentions": [{"start": 96, "end": 108, "username": "TargetedOnc", "id": "726304448"}], "annotations": [{"start": 186, "end": 195, "probability": 0.7822, "type": "Other", "normalized_text": "Karyopharm"}], "urls": [{"start": 217, "end": 240, "url": "https://t.co/lY1whIeggs", "expanded_url": "https://www.targetedonc.com/view/clinical-commentary-dose-reduction-of-selinexor-in-relapsed-patients-with-multiple-myeloma", "display_url": "targetedonc.com/view/clinical-\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1599161806685147138/e_rIthTy?format=jpg&name=orig", "width": 480, "height": 270}, {"url": "https://pbs.twimg.com/news_img/1599161806685147138/e_rIthTy?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Clinical Commentary: Dose Reduction of Selinexor in Relapsed Patients With Multiple Myeloma", "description": "At a live virtual event, Sumit Madan, MD, broke down the use of quadruplet therapies in the frontline setting for patients with multiple myeloma and how to care for patients when they relapse on treatment.", "unwound_url": "https://www.targetedonc.com/view/clinical-commentary-dose-reduction-of-selinexor-in-relapsed-patients-with-multiple-myeloma"}]}, "edit_history_tweet_ids": ["1599445097224892418"], "source": "Twitter Web App", "created_at": "2022-12-04T16:46:42.000Z"}, {"text": "@ManniMD1 I'm a myeloma coach and humble student of this complex disease, but why would anyone who is only intermediate risk smoldering subject themselves to the potential side effects of this drug?? Only serves Karyopharm's interest in increasing market share.", "conversation_id": "1599057168103538690", "lang": "en", "author_id": "913851074", "id": "1599416272323690496", "referenced_tweets": [{"type": "replied_to", "id": "1599057168103538690"}], "entities": {"mentions": [{"start": 0, "end": 9, "username": "ManniMD1", "id": "1269642863924609025"}], "annotations": [{"start": 16, "end": 22, "probability": 0.5332, "type": "Other", "normalized_text": "myeloma"}, {"start": 212, "end": 221, "probability": 0.6271, "type": "Other", "normalized_text": "Karyopharm"}]}, "edit_history_tweet_ids": ["1599416272323690496"], "in_reply_to_user_id": "1269642863924609025", "source": "Twitter Web App", "created_at": "2022-12-04T14:52:09.000Z"}, {"text": "The U Chicago Leukemia/myeloid program Twitter account is up and running! Give it a follow at @UChicagoLeuk\n\n@myeloidmalig @AyaOncologist @michaelwd  @CanerSaygin @RoloffGreg @HowellJollyBody @mariamtn89 @gvencut1", "conversation_id": "1599219692559745024", "lang": "en", "author_id": "2417458314", "id": "1599219692559745024", "entities": {"mentions": [{"start": 94, "end": 107, "username": "UChicagoLeuk", "id": "1599205265928224768"}, {"start": 109, "end": 122, "username": "myeloidmalig", "id": "433627422"}, {"start": 123, "end": 137, "username": "AyaOncologist", "id": "1189289857845088256"}, {"start": 138, "end": 148, "username": "michaelwd", "id": "10056172"}, {"start": 150, "end": 162, "username": "CanerSaygin", "id": "2234768227"}, {"start": 163, "end": 174, "username": "RoloffGreg", "id": "1268610580740550656"}, {"start": 175, "end": 191, "username": "HowellJollyBody", "id": "603145861"}, {"start": 192, "end": 203, "username": "mariamtn89", "id": "1362922953076334592"}, {"start": 204, "end": 213, "username": "gvencut1", "id": "908519925672792064"}], "annotations": [{"start": 6, "end": 21, "probability": 0.3438, "type": "Other", "normalized_text": "Chicago Leukemia"}, {"start": 23, "end": 29, "probability": 0.5868, "type": "Other", "normalized_text": "myeloid"}, {"start": 39, "end": 45, "probability": 0.8731, "type": "Other", "normalized_text": "Twitter"}]}, "edit_history_tweet_ids": ["1599219692559745024"], "source": "Twitter for iPhone", "created_at": "2022-12-04T01:51:01.000Z"}, {"text": "The fact 20,000 people are tuning into a discussion on whether we ought to treat smoldering myeloma is incredible. \ud83d\udc47\ud83d\udc47 Twitter is really a powerful force. I hope it continues to improve :) https://t.co/KiX8sHXVJy", "conversation_id": "1599210886518173697", "lang": "en", "author_id": "1194962714", "id": "1599210886518173697", "referenced_tweets": [{"type": "quoted", "id": "1599126088411541504"}], "entities": {"annotations": [{"start": 92, "end": 98, "probability": 0.5821, "type": "Other", "normalized_text": "myeloma"}, {"start": 118, "end": 124, "probability": 0.9812, "type": "Other", "normalized_text": "Twitter"}], "urls": [{"start": 188, "end": 211, "url": "https://t.co/KiX8sHXVJy", "expanded_url": "https://twitter.com/VPrasadMDMPH/status/1599126088411541504", "display_url": "twitter.com/VPrasadMDMPH/s\u2026"}]}, "edit_history_tweet_ids": ["1599210886518173697"], "source": "Twitter Web App", "created_at": "2022-12-04T01:16:01.000Z"}, {"text": "@AaronGoodman33 @BrownHospMed You need a better conditioner", "conversation_id": "1599142217792516096", "lang": "en", "author_id": "18792477", "id": "1599207509738209280", "referenced_tweets": [{"type": "replied_to", "id": "1599192787391778820"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 29, "username": "BrownHospMed", "id": "1493597471074832393"}]}, "edit_history_tweet_ids": ["1599207509738209280"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for iPad", "created_at": "2022-12-04T01:02:36.000Z"}, {"text": "@AaronGoodman33 @BrownHospMed Thats a variant.", "conversation_id": "1599142217792516096", "lang": "en", "author_id": "1117857169528033280", "id": "1599193443711930369", "referenced_tweets": [{"type": "replied_to", "id": "1599192787391778820"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 29, "username": "BrownHospMed", "id": "1493597471074832393"}]}, "edit_history_tweet_ids": ["1599193443711930369"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter Web App", "created_at": "2022-12-04T00:06:43.000Z"}, {"text": "A 60-year-old man presented with a 6-month history of fatigue, weight loss, and gingival bleeding. Physical examination suggested the presence of a massively enlarged spleen. Labs w/ thrombocytopenia and lymphocytosis. What is the likely diagnosis? #Medtwitter https://t.co/cDE8Os23wh", "conversation_id": "1599142217792516096", "lang": "en", "author_id": "1493597471074832393", "id": "1599142217792516096", "entities": {"annotations": [{"start": 183, "end": 198, "probability": 0.7288, "type": "Other", "normalized_text": "thrombocytopenia"}, {"start": 204, "end": 216, "probability": 0.6873, "type": "Other", "normalized_text": "lymphocytosis"}, {"start": 250, "end": 259, "probability": 0.4527, "type": "Other", "normalized_text": "Medtwitter"}], "urls": [{"start": 261, "end": 284, "url": "https://t.co/cDE8Os23wh", "expanded_url": "https://twitter.com/BrownHospMed/status/1599142217792516096/photo/1", "display_url": "pic.twitter.com/cDE8Os23wh", "media_key": "3_1599142212830466049"}], "hashtags": [{"start": 249, "end": 260, "tag": "Medtwitter"}]}, "edit_history_tweet_ids": ["1599142217792516096"], "source": "Twitter Web App", "created_at": "2022-12-03T20:43:10.000Z"}, {"text": "Now on the audio feed @Plenary_Session! https://t.co/eqgQ6iPtPd", "conversation_id": "1599137975329492992", "lang": "en", "author_id": "1028063001755103233", "id": "1599137975329492992", "referenced_tweets": [{"type": "quoted", "id": "1599126088411541504"}], "entities": {"mentions": [{"start": 22, "end": 38, "username": "Plenary_Session", "id": "1028063001755103233"}], "urls": [{"start": 40, "end": 63, "url": "https://t.co/eqgQ6iPtPd", "expanded_url": "https://twitter.com/VPrasadMDMPH/status/1599126088411541504", "display_url": "twitter.com/VPrasadMDMPH/s\u2026"}]}, "edit_history_tweet_ids": ["1599137975329492992"], "source": "Twitter Web App", "created_at": "2022-12-03T20:26:18.000Z"}, {"text": "Why I love Twitter\u2026 https://t.co/3Dz9YDwTVC", "conversation_id": "1599145203348082689", "lang": "en", "author_id": "461579451", "id": "1599145203348082689", "referenced_tweets": [{"type": "quoted", "id": "1599126088411541504"}], "entities": {"annotations": [{"start": 11, "end": 17, "probability": 0.9772, "type": "Other", "normalized_text": "Twitter"}], "urls": [{"start": 20, "end": 43, "url": "https://t.co/3Dz9YDwTVC", "expanded_url": "https://twitter.com/VPrasadMDMPH/status/1599126088411541504", "display_url": "twitter.com/VPrasadMDMPH/s\u2026"}]}, "edit_history_tweet_ids": ["1599145203348082689"], "source": "Twitter for iPhone", "created_at": "2022-12-03T20:55:01.000Z"}, {"text": "Wow! Great new video series from Vinay !\nI enjoyed it a lot !\n\nMed Twitter is alive, for sure !\nWell done \ud83d\udc4f https://t.co/sdrdvtEjvK", "conversation_id": "1599169972072169472", "lang": "en", "author_id": "1472332068914962433", "id": "1599169972072169472", "referenced_tweets": [{"type": "quoted", "id": "1599126088411541504"}], "entities": {"annotations": [{"start": 33, "end": 37, "probability": 0.7528, "type": "Other", "normalized_text": "Vinay"}, {"start": 67, "end": 73, "probability": 0.9881, "type": "Other", "normalized_text": "Twitter"}], "urls": [{"start": 108, "end": 131, "url": "https://t.co/sdrdvtEjvK", "expanded_url": "https://twitter.com/VPrasadMDMPH/status/1599126088411541504", "display_url": "twitter.com/VPrasadMDMPH/s\u2026"}]}, "edit_history_tweet_ids": ["1599169972072169472"], "source": "Twitter Web App", "created_at": "2022-12-03T22:33:27.000Z"}, {"text": "We are hiring!!! We are looking to add to our lovely Breast Medical Oncology Team @UCSDCancer if you are interested please let me know!", "conversation_id": "1599082579202027521", "lang": "en", "author_id": "1068352638499020800", "id": "1599082579202027521", "entities": {"mentions": [{"start": 82, "end": 93, "username": "UCSDCancer", "id": "1473383250995281922"}], "annotations": [{"start": 53, "end": 75, "probability": 0.649, "type": "Other", "normalized_text": "Breast Medical Oncology"}]}, "edit_history_tweet_ids": ["1599082579202027521"], "source": "Twitter for iPhone", "created_at": "2022-12-03T16:46:11.000Z"}, {"text": "Plenary Session Downloads are Insane\nMillions of downloads &amp; growing\nMost Popular Heme Onc Podcast Globally\nThanks to the listeners!\n@VPrasadMDMPH https://t.co/aZBkb3BvVp", "conversation_id": "1599138243228073985", "lang": "en", "author_id": "1028063001755103233", "id": "1599138243228073985", "entities": {"mentions": [{"start": 137, "end": 150, "username": "VPrasadMDMPH", "id": "1194962714"}], "urls": [{"start": 151, "end": 174, "url": "https://t.co/aZBkb3BvVp", "expanded_url": "https://twitter.com/Plenary_Session/status/1599138243228073985/photo/1", "display_url": "pic.twitter.com/aZBkb3BvVp", "media_key": "3_1599138043855708160"}]}, "edit_history_tweet_ids": ["1599138243228073985"], "source": "Twitter Web App", "created_at": "2022-12-03T20:27:22.000Z"}, {"text": "A Twitter Battle on Treating HR Risk Smoldering Myeloma\nI break down the debate and arguments\nA 3 part video series just in time for #ASH22\n(a clearer video uploading to Youtube, will post link at end of video)\n@Plenary_Session @AaronGoodman33 \nPART 1 - The battle starts https://t.co/MhLvKAXP29", "conversation_id": "1599126088411541504", "lang": "en", "author_id": "1194962714", "id": "1599126088411541504", "entities": {"mentions": [{"start": 211, "end": 227, "username": "Plenary_Session", "id": "1028063001755103233"}, {"start": 228, "end": 243, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 2, "end": 8, "probability": 0.9727, "type": "Other", "normalized_text": "Twitter"}, {"start": 48, "end": 54, "probability": 0.5988, "type": "Other", "normalized_text": "Myeloma"}, {"start": 134, "end": 138, "probability": 0.727, "type": "Other", "normalized_text": "ASH22"}, {"start": 170, "end": 176, "probability": 0.967, "type": "Other", "normalized_text": "Youtube"}], "urls": [{"start": 272, "end": 295, "url": "https://t.co/MhLvKAXP29", "expanded_url": "https://twitter.com/VPrasadMDMPH/status/1599126088411541504/video/1", "display_url": "pic.twitter.com/MhLvKAXP29", "media_key": "7_1599123197223280641"}], "hashtags": [{"start": 133, "end": 139, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1599126088411541504"], "source": "Twitter Web App", "created_at": "2022-12-03T19:39:04.000Z"}, {"text": "No one is forcing you to treat HRSMM. An expert in the field presented  his reasoning. I don\u2019t treat HR SMM-stop with the patriarchal approach to Medicine. \nDiscuss data with the patient and let them make a decision. Every day is a rant on why  someone else\u2019s approach is wrong. https://t.co/sRtYz7WxIi", "conversation_id": "1599115678836924416", "lang": "en", "author_id": "28731834", "id": "1599115678836924416", "referenced_tweets": [{"type": "quoted", "id": "1598826846082121728"}], "entities": {"annotations": [{"start": 31, "end": 35, "probability": 0.5531, "type": "Other", "normalized_text": "HRSMM"}, {"start": 104, "end": 106, "probability": 0.4639, "type": "Other", "normalized_text": "SMM"}], "urls": [{"start": 279, "end": 302, "url": "https://t.co/sRtYz7WxIi", "expanded_url": "https://twitter.com/aarongoodman33/status/1598826846082121728", "display_url": "twitter.com/aarongoodman33\u2026"}]}, "edit_history_tweet_ids": ["1599115678836924416"], "source": "Twitter for iPhone", "created_at": "2022-12-03T18:57:42.000Z"}, {"text": "@AaronGoodman33 @chadinabhan I would never say that blafesmy.\nBut I must point out my Nirvana superfan days are long gone. \nToday Im an old man, who likes Beatles, Eagles and all Yatch Rock bands...", "conversation_id": "1598826846082121728", "lang": "en", "author_id": "1294745239656202240", "id": "1599110786210676736", "referenced_tweets": [{"type": "replied_to", "id": "1599107232825999360"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 16, "end": 28, "username": "chadinabhan", "id": "2212735524"}], "annotations": [{"start": 86, "end": 92, "probability": 0.9222, "type": "Organization", "normalized_text": "Nirvana"}, {"start": 155, "end": 161, "probability": 0.9826, "type": "Organization", "normalized_text": "Beatles"}, {"start": 164, "end": 169, "probability": 0.8985, "type": "Organization", "normalized_text": "Eagles"}, {"start": 179, "end": 188, "probability": 0.7441, "type": "Organization", "normalized_text": "Yatch Rock"}]}, "edit_history_tweet_ids": ["1599110786210676736"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter Web App", "created_at": "2022-12-03T18:38:16.000Z"}, {"text": "@AaronGoodman33 Chronic Granulomatous Disease\n\ndefective function of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase\n\nNitroblue tetrazolium blood test https://t.co/zLRE7dZG5A", "conversation_id": "1599096602895200256", "lang": "en", "author_id": "821765042051784705", "id": "1599106602958999552", "referenced_tweets": [{"type": "replied_to", "id": "1599096602895200256"}], "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}], "annotations": [{"start": 16, "end": 44, "probability": 0.84, "type": "Other", "normalized_text": "Chronic Granulomatous Disease"}, {"start": 94, "end": 105, "probability": 0.4637, "type": "Other", "normalized_text": "dinucleotide"}, {"start": 118, "end": 122, "probability": 0.6777, "type": "Other", "normalized_text": "NADPH"}, {"start": 125, "end": 131, "probability": 0.5506, "type": "Other", "normalized_text": "oxidase"}, {"start": 134, "end": 165, "probability": 0.5706, "type": "Other", "normalized_text": "Nitroblue tetrazolium blood test"}], "urls": [{"start": 167, "end": 190, "url": "https://t.co/zLRE7dZG5A", "expanded_url": "https://twitter.com/Sthanu5/status/1599106602958999552/photo/1", "display_url": "pic.twitter.com/zLRE7dZG5A", "media_key": "3_1599106598076444672"}]}, "edit_history_tweet_ids": ["1599106602958999552"], "in_reply_to_user_id": "854692626015993857", "source": "Twitter for Android", "created_at": "2022-12-03T18:21:38.000Z"}, {"text": "Congrats to @MRLitzow @SelinaLugerMD @MartinTallman E. Paietta , Z.Sun &amp; the rest of @eaonc team! This trial is one that keeps on giving, including \ud83d\udc4c\ud83c\udffbknowledge on the biology of B-ALL also from samples collected from pts on this trial thanks to @CMullighan and team. #ASH22 https://t.co/F7GUXBE9Th", "conversation_id": "1599115085322285056", "lang": "en", "author_id": "3076847052", "id": "1599115085322285056", "referenced_tweets": [{"type": "quoted", "id": "1599095143818473472"}], "entities": {"mentions": [{"start": 12, "end": 21, "username": "MRLitzow", "id": "973216285"}, {"start": 22, "end": 36, "username": "SelinaLugerMD", "id": "4827569945"}, {"start": 37, "end": 51, "username": "MartinTallman", "id": "1334487799718961153"}, {"start": 89, "end": 95, "username": "eaonc", "id": "2201478360"}, {"start": 249, "end": 260, "username": "CMullighan", "id": "1579638991"}], "annotations": [{"start": 52, "end": 61, "probability": 0.5572, "type": "Other", "normalized_text": "E. Paietta"}, {"start": 65, "end": 69, "probability": 0.6797, "type": "Other", "normalized_text": "Z.Sun"}], "urls": [{"start": 278, "end": 301, "url": "https://t.co/F7GUXBE9Th", "expanded_url": "https://twitter.com/AaronGoodman33/status/1599095143818473472", "display_url": "twitter.com/AaronGoodman33\u2026"}], "hashtags": [{"start": 271, "end": 277, "tag": "ASH22"}]}, "edit_history_tweet_ids": ["1599115085322285056"], "source": "Twitter for iPhone", "created_at": "2022-12-03T18:55:21.000Z"}]}, "errors": [{"value": "1599440890803630081", "detail": "Could not find tweet with referenced_tweets.id: [1599440890803630081].", "title": "Not Found Error", "resource_type": "tweet", "parameter": "referenced_tweets.id", "resource_id": "1599440890803630081", "type": "https://api.twitter.com/2/problems/resource-not-found"}], "meta": {"next_token": "7140dibdnow9c7btw424ch4cxkmkdd0jqtnnesj6g05kk", "result_count": 100, "newest_id": "1601410660222783489", "oldest_id": "1599116192475910144"}, "neighbors": ["2212735524", "1269642863924609025", "854692626015993857", "1194962714", "824315782947631104", "1331336294828437504", "999010996034338818"]}